
WHAT IS CLAIMED IS:

1. A compound of formula I



5

20


25

wherein each of ${\tt A}^1$ and ${\tt A}^2$ is independently C, CH or N; wherein ring A is selected from

a) 5- or 6-membered partially saturated heterocyclyl,

I

- 10 b) 5- or 6-membered heteroaryl,
 - c) 9-, 10- or 11-membered fused partially saturated heterocyclyl,
 - d) 9-, 10- or 11-membered fused heteroaryl,
 - e) aryl, and
- f) 4-, 5- or 6-membered cycloalkenyl;



wherein X is

wherein Z is oxygen or sulfur; wherein R is selected from

- a) substituted or unsubstituted 4-6 membered heterocyclyl,
- b) substituted aryl, and
- c) substituted or unsubstituted fused 9-14-membered bicyclic or tricyclic heterocyclyl; wherein substituted R is substituted with one or more substituents independently selected from halo, -OR³,

20

 $-SR^3$, $-SO_2R^3$, $-CO_2R^3$, $-COR^3R^3$, $-COR^3$, $-NR^3R^3$, $-SO_2NR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)R^3$, cycloalkyl, optionally substituted 3-6 membered heterocyclyl, optionally substituted phenyl, nitro, alkylaminoalkoxyalkoxy, cyano, oxox, alkylaminoalkoxy, lower alkyl substituted with R^2 , lower alkenyl substituted with R^2 , and lower alkynyl substituted with R^2 ;

wherein R1 is selected from

- a) substituted or unsubstituted 6-10 membered aryl,
- b) substituted or unsubstituted 4-6 membered heterocyclyl,
 - c) substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl,
 - d) cycloalkyl, and
- 15 e) cycloalkenyl,

wherein substituted R^1 is substituted with one or more substituents independently selected from halo, $-OR^3$, $-SR^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-NH(C_1-C_4$ alkylenyl R^{14}), $-SO_2R^3$, $-SO_2NR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)NR^3R^3$, optionally substituted cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, halosulfonyl, cyano, alkylaminoalkoxy, alkylaminoalkoxyalkoxy, nitro, lower alkyl

substituted with R^2 , lower alkenyl substituted with R^2 , and lower alkynyl substituted with R^2 ;

wherein R^2 is one or more substituents independently selected from H, halo, $-OR^3$, oxo, $-SR^3$, $-CO_2R^3$, $-COR^3$, $-CONR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)R^3$, cycloalkyl,

optionally substituted phenylalkylenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted heteroarylalkylenyl, optionally substituted phenyl, lower alkyl, cyano, lower hydroxyalkyl, lower carboxyalkyl, nitro, C₁₋₆-alkoxy-C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-

 $_6$ -alkoxy- C_{1-6} -alkoxy, lower alkenyl, lower alkynyl, lower aminoalkyl, lower alkylaminoalkyl and lower haloalkyl; wherein R^3 is independently selected from H, lower alkyl, optionally substituted phenyl, optionally substituted 3-6 membered heterocyclyl, optionally substituted C_3 - C_6 -cycloalkyl, optionally substituted phenylalkyl, optionally substituted 3-6 membered heterocyclylalkyl, optionally substituted C_3 - C_6 cycloalkylalkyl, and lower haloalkyl;

wherein R^4 is selected from a direct bond, C_{2-4} -alkylenyl, C_{2-4} -alkenylenyl and C_{2-4} -alkynylenyl, where one of the CH_2 groups may be replaced with an oxygen atom or an -NH-, wherein R^4 is optionally substituted with hydroxy;

wherein R⁵ is selected from H, lower alkyl, optionally substituted phenyl and optionally substituted lower aralkyl;

- wherein R^{14} is selected from H, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl and optionally substituted C_3 - C_6 cycloalkyl;
- and pharmaceutically acceptable derivatives thereof; provided A is not pyridyl when X is -C(0)NH- and when R¹ is 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl when R⁵ is methyl and when R is 4-methylpiperidyl;

R⁵ is H, when R² is 6-methyl and when R is indazolyl; further provided A is not phenyl when X is -C(0)NH-, when R¹ is phenyl, 4-bromophenyl, 2-methylphenyl, 4methoxyphenyl, when R⁵ is H and when R is 4-pyridyl;

further provided A is not pyridyl when X is -C(0)NH-, when

further provided A is not phenyl when X is -C(0)NH-, when R¹ is phenyl, when R⁵ is H and when R is 2-oxobenzopyan-4-yl;

further provided A is not phenyl when X is -C(0)NH-, when R^1 is phenyl, 4-chlorophenyl, 3-nitrophenyl, 4-methoxyphenyl, when R^5 is H and when R is 4-imidazolinyl;

- further provided A is not phenyl when X is -C(0)NH-, when R^5 is H, when R^{5a} is substituted benzyl and when R is substituted triazinyl;
- further provided A is not phenyl when X is -C(O)NH-, when R¹ is phenyl or 2-chlorophenyl, when R⁵ is H and when R is 4-quinazolinyl;
 - further provided A is not phenyl when X is -C(0)NH-, when R^1 is phenyl, when R^5 is H and when R is isoquinolin-1-yl;
- further provided A is not phenyl when X is -C(0)NH-, when R¹

 10 is 2-chlorophenyl or 4-chlorophenyl, when R⁵ is H and when R is 3-chloroisoquinolin-1-yl;
 - further provided A is not phenyl when X is -C(0)NH-, when R^1 is 1-ethylpiperid-3-yl or 1-ethylpiperid-4-yl, when R^5 is H and when R is 8-trifluoromethylquinolin-4-yl;
- further provided A is not phenyl when X is -C(0)NH-, when R¹
 is 1-ethylpiperid-3-yl, when R⁵ is H and when R is 8chloroquinolin-4-yl;
 - further provided A is not phenyl when X is -C(0)NH-, when R¹ is halo substituted phenyl, 1-butylpiperid-4-yl, 1-ethylpiperid-3-yl or 1-ethylpiperid-4-yl, when R⁵ is H and when R is 7-chloroquinolin-4-yl; and
 - further provided R is not unsubstituted 2-thienyl, unsubstituted 2-pyridyl or unsubstituted 3-pyridyl.
- 25 2. Compound of Claim 1, and pharmaceutically acceptable derivatives thereof, wherein A is selected from 5- or 6- membered partially saturated heterocyclyl.
- 3. Compound of Claim 2, wherein A is selected from dihydropyran, dihydrothienyl, dihydrofuryl, oxodihydrofuryl, pyrrolinyl, dihydrothiazolyl, dihydrooxazolyl, dihydro-isothiazolyl, dihydro-isoxazolyl,

imidazolinyl and pyrazolinyl; wherein X is selected from

$$\begin{array}{c}
0 \\
N \\
R^{5a}
\end{array}$$
 and
$$\begin{array}{c}
R^{4a} \\
R^{5a}
\end{array}$$

wherein R is selected from substituted or unsubstituted 5-6 membered heteroaryl comprising one or more nitrogen atoms,

- substituted phenyl and substituted or unsubstituted 9-10 membered bicyclic or 13-14 membered tricyclic heterocyclyl; wherein substituted R is substituted with one or more substituents independently selected from halo, -OR³, -SR³, -SO₂R³, -CO₂R³, -CO₂R³, -COR³R³, -NR³R³, -NR³C(O)OR³, -
- wherein R¹ is selected from substituted or unsubstituted aryl selected from phenyl, naphthyl, indanyl, indenyl and tetrahydronaphthyl, substituted or unsubstituted 5-6 membered heteroaryl, C₃₋₆-cycloalkyl, and substituted or unsubstituted 9-14 membered bicyclic or tricyclic
- heterocyclyl; wherein substituted R^1 is substituted with one or more substituents independently selected from halo, $-OR^3$, OXO, $-SR^3$, $-SO_2R^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-NH(C_1-C_4$ alkylenyl R^3), $-(C_1-C_4$ alkylenyl) NR^3R^3 , $-SO_2NR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)R^3$, C_1-C_6 -alkylamino- C_1-C_6 -alkoxy, C_1-C_6 -alkylamino- C_1 -
- C₆-alkoxy- $C_{1-}C_{6}$ -alkoxy, halosulfonyl, optionally substituted 4-6 membered heterocyclylcarbonylalkyl, C_{1-4} -

alkoxycarbonylamino- C_{1-6} -alkyl, R^7 optionally substituted C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, optionally substituted phenyl, optionally

substituted 4-6 membered heterocyclyl- C_1 - C_6 -alkylenyl, 4-6 membered heterocyclyl- C_2 - C_6 -alkenylenyl, C_{1-4} -alkyl, cyano, C_{1-4} $_4$ -hydroxyalkyl, nitro and C_{1-4} -haloalkyl; wherein R^2 is one or more substituents independently selected from H, halo, - $\texttt{OR}^3, \ \texttt{oxo}, \ -\texttt{SR}^3, \ -\texttt{CO}_2 \texttt{R}^3, \ -\texttt{CONR}^3 \texttt{R}^3, \ -\texttt{COR}^3, \ -\texttt{NR}^3 \texttt{R}^3, \ -\texttt{SO}_2 \texttt{NR}^3 \texttt{R}^3, \ NR^3C(O)OR^3$, $-NR^3C(O)R^3$, C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, C_{1-6} -alkyl, cyano, C_{1-4} -hydroxyalkyl, C_{1-4} carboxyalkyl, nitro, C_{2-3} -alkenyl, C_{2-3} -alkynyl and C_{1-4} haloalkyl; wherein \mbox{R}^3 is independently selected from H, $\mbox{C}_{1\text{-}4\text{-}}$ 10 alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-4} -alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkyl, optionally substituted C_3 - C_6 cycloalkyl and C_{1-2} -haloalkyl; wherein R^{4a} is C_{2-4} -alkylenyl, 15 where one of the CH_2 groups may be replaced with an oxygen atom or an -NH-; wherein R^{4a} is optionally substituted with hydroxy; wherein R^5 is selected from H and C_{1-2} -alkyl; wherein R^{5a} is selected from H and C_{1-2} -alkyl; wherein R^{e} and R^{f} are independently selected from H and $C_{1\text{--}2}\text{-}haloalkyl;$ and 20 wherein R^7 is selected from H, C_{1-6} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-6} -alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl- C_{1-6} -alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered 25 heterocyclyl- $C_{1-}C_{6}$ -alkyl, C_{1-4} -alkoxy- C_{1-4} -alkyl and C_{1-4} -

4. Compound of Claim 1, and pharmaceutically acceptable derivatives thereof, wherein A is selected from 5- or 6- membered heteroaryl.

derivatives thereof.

alkoxy- $C_{1\text{--}4}$ -alkoxy- $C_{1\text{--}4}$ -alkyl, and pharmaceutically acceptable

15

20

25

30

5. Compound of Claim 4, wherein A is selected from pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl, isoxazolyl, triazolyl and isothiazolyl; wherein X is selected from

wherein R is selected from substituted or unsubstituted 5-6 membered heteroaryl comprising one or more nitrogen atoms, substituted phenyl and substituted or unsubstituted 9-10 membered bicyclic or 13-14 membered tricyclic heterocyclyl; wherein substituted R is substituted with one or more substituents independently selected from halo, -OR3, -SR3, - SO_2R^3 , $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-SO_2NR^3R^3$, $-NR^3C$ (O)OR 3 , - $NR^3C(0)R^3$, C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, nitro, C_{1-4} -alkylamino- C_{1-4} -alkoxy- C_{1-4} -alkoxy, cyano, C_{1-4} -alkylamino- C_{1-4} -alkoxy, C_{1-2} -alkyl substituted with R^2 , C_{2-3} -alkenyl substituted with R^2 , and C_{2-3} -alkynyl substituted with R^2 ; wherein R1 is selected from substituted or unsubstituted aryl selected from phenyl, naphthyl, indanyl, indenyl and tetrahydronaphthyl, substituted or unsubstituted 5-6 membered heteroaryl, C_{3-6} -cycloalkyl, and substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl; wherein substituted R1 is substituted with one or more substituents independently selected from halo, -OR3, oxo, $-SR^3$, $-SO_2R^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-NH(C_1-C_4)$ $\texttt{alkylenylR}^3)\,,\; -(\texttt{C}_1-\texttt{C}_4\;\;\texttt{alkylenyl})\,\texttt{NR}^3\texttt{R}^3\,,\; -\texttt{SO}_2\texttt{NR}^3\texttt{R}^3\,,\; -\texttt{NR}^3\texttt{C}\,(\texttt{O})\,\texttt{OR}^3\,,$ $-NR^3C\left(0\right)R^3,\ C_{1-}C_{6}-alkylamino-C_{1-}C_{6}-alkoxy,\ C_{1-}C_{6}-alkylamino-C_{1 C_6$ -alkoxy- C_1 - C_6 -alkoxy, halosulfonyl, optionally substituted 4-6 membered heterocyclylcarbonylalkyl, C_{1-4} -

alkoxycarbonylamino-C₁₋₆-alkyl, substituted C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-6} -alkylenyl, optionally substituted 4-6 membered heterocyclyl- C_1 - C_6 -alkylenyl, 4-6 membered heterocyclyl- C_2 - C_6 -alkenylenyl, C_{1-6} -alkyl, cyano, C_{1-6} $_4$ -hydroxyalkyl, nitro and C_{1-4} -haloalkyl; wherein R^2 is one or more substituents independently selected from H, halo, - OR^3 , OXO, $-SR^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-SO_2NR^3R^3$, $-SO_2NR^3R^3$ $NR^3C(0)OR^3$, $-NR^3C(0)R^3$, C_{3-6} -cycloalkyl, optionally 10 substituted 4-6 membered heterocyclyl, optionally substituted phenyl, C_{1-6} -alkyl, cyano, C_{1-4} -hydroxyalkyl, C_{1-4} carboxyalkyl, nitro, C_{2-3} -alkenyl, C_{2-3} -alkynyl and C_{1-4} haloalkyl; wherein R^3 is independently selected from H, $C_{1\text{-}4\text{-}}$ alkyl, optionally substituted phenyl, optionally substituted 15 phenyl- C_{1-4} -alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkyl, optionally substituted C_3 - C_6 cycloalkyl and C_{1-2} -haloalkyl; wherein R^{4a} is C_{2-4} -alkylenyl, where one of the ${
m CH_2}$ groups may be replaced with an oxygen 20 atom or an -NH-; wherein R^{4a} is optionally substituted with hydroxy; wherein R^5 is selected from H and C_{1-2} -alkyl; wherein R^{5a} is selected from H and C_{1-2} -alkyl; wherein R^{e} and R^{f} are independently selected from H and C_{1-2} -haloalkyl; and wherein R^7 is selected from H, C_{1-6} -alkyl, optionally 25 substituted phenyl, optionally substituted phenyl- C_{1-6} -alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- C_1 - C_6 -alkyl, C_{1-4} alkoxy- C_{1-4} -alkyl and C_{1-4} -alkoxy- C_{1-4} -alkoxy- C_{1-4} -alkyl, and pharmaceutically acceptable derivatives thereof. 30

6. Compound of Claim 1 wherein A is selected from

15

wherein R° is selected from H, methyl and optionally substituted phenyl; wherein X is selected from

$$\bigvee_{\substack{N \\ R^{5a}}}^{N} \bigcap_{\substack{n \\ R^{5a}}}^{N} \bigcap_{\substack{n \\ R^{5a}}}^{R^{4a}} ; \text{ wherein R is selected}$$

from substituted or unsubstituted pyrazolyl, triazolyl, pyridyl, pyrimidinyl, and pyridazinyl, substituted phenyl, indazolyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, benzotriazolyl, 2,3-dihydrobenzofuryl, 2-oxo-1,2-dihydroquinol-7-yl, naphthyridinyl and quinazolinyl; wherein substituted R is substituted with one or more substituents independently selected from halo, hydroxy, C_{1-4} -alkyl, C_{1-2} -alkoxy, optionally substituted 4-6 membered heterocyclyl- C_{1-2} -alkoxy, amino, C_{1-2} -alkylamino, aminosulfonyl, -NR 3 C(0)OR 3 ,

 $-NR^3C(0)\,R^3,\ C_{3-6}\text{-cycloalkyl, optionally substituted 4-6}$ membered heterocyclyl, optionally substituted phenyl, nitro, $C_{1-2}\text{-alkylamino-}C_{1-2}\text{-alkoxy-}C_{1-2}\text{-alkoxy, cyano, }C_{1-2}\text{-alkylamino-}C_{1-2}\text{-alkylamino-}C_{1-2}\text{-alkylamino-}C_{2-3}\text{-alkylamino-}C_{1-2}\text{-alkylamino-}C_{2-3}\text{-alkylamino-}C$

alkynyl, C_{1-2} -hydroxyalkyl, C_{1-2} -aminoalkyl, C_{1-2} -haloalkyl, optionally substituted 4-6 membered heterocyclyl- C_{2-3} -alkenyl, and optionally substituted 4-6 membered heterocyclyl- C_{2-3} -alkynyl; wherein R^1 is selected from substituted or unsubstituted aryl selected from phenyl,

10 naphthyl, indanyl, indenyl and tetrahydronaphthyl, substituted or unsubstituted 5-6 membered heteroaryl, C_{3-6} -cycloalkyl, and substituted or unsubstituted 9-10 membered bicyclic or 13-14 membered tricyclic heterocyclyl; wherein substituted R^1 is substituted with one or more substituents

independently selected from halo, C_{1-6} -alkyl, optionally substituted C_{3-6} -cycloalkyl, optionally substituted phenyl, optionally substituted phenyl- $C_{1-}C_{4}$ -alkylenyl, C_{1-2} -haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl- $C_{1-}C_{4}$ -alkylenyl,

optionally substituted 4-6 membered heterocyclyl-C₂₋C₄alkenylenyl, optionally substituted 4-6 membered
heterocyclyl, optionally substituted 4-6 membered
heterocyclyloxy, optionally substituted 4-6 membered
heterocyclylsulfonyl, optionally substituted 4-6 membered

heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl-C₁₋₄-alkylcarbonyl, C₁₋₂-haloalkyl, C₁₋₄-aminoalkyl, nitro, amino, hydroxy, oxo, cyano, aminosulfonyl, C₁₋₂-alkylsulfonyl, halosulfonyl, C₁₋₄-

alkylcarbonyl, C_{1-3} -alkylamino- C_{1-3} -alkyl, C_{1-3} -alkylamino- C_{1-3} -alkoxy, C_{1-3} -alkylamino- C_{1-3} -alkoxy- C_{1-3} -alkoxy, C_{1-4} -alkoxycarbonyl, C_{1-4} -alkoxycarbonylamino- C_{1-4} -alkyl, C_{1-4} -

hydroxyalkyl,
$$R^e \rightarrow R^f R^7$$
 and C_{1-4} -alkoxy; wherein R^2 is one

north

or more substituents independently selected from H, halo, hydroxy, C_{1-2} -alkoxy, C_{1-2} -haloalkoxy, amino, C_{1-2} -alkylamino, optionally substituted 4-6 membered heterocyclyl- C_{1-2} alkylamino, aminosulfonyl, C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, C_{1-4} -alkyl, cyano, C_{1-2} -hydroxyalkyl, C_{1-3} carboxyalkyl, nitro, C_{2-3} -alkenyl, C_{2-3} -alkynyl and C_{1-2} haloalkyl; wherein R^3 is independently selected from H, $C_{1\text{-}4}\text{-}$ alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-4} -alkyl, optionally substituted 4-6 membered 10 heterocyclyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkyl, optionally substituted C_3 - C_6 cycloalkyl and C_{1-2} -haloalkyl; wherein R^{4a} is C_{2-3} -alkylenyl where one of the $ext{CH}_2$ groups may be replaced with an oxygen atom or an -NH-, wherein R^{4a} is optionally substituted with 15 hydroxy; wherein R^5 is selected from H and C_{1-2} -alkyl; wherein R^{5a} is selected from H and C_{1-2} -alkyl; wherein R^{e} and R^{f} are independently selected from H and C_{1-2} -haloalkyl; and wherein R^7 is selected from H, C_{1-3} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-3} -alkyl, 20 optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- C_1 - C_3 -alkyl, C_{1-3} alkoxy- C_{1-2} -alkyl and C_{1-3} -alkoxy- C_{1-3} -alkoxy- C_{1-3} -alkyl, and pharmaceutically acceptable derivatives thereof.

7. Compound of Claim 6 wherein A is selected from

$$\downarrow_{S}^{N}$$
, \downarrow_{N}^{N} and \downarrow_{N}^{N}

wherein R^c is selected from H, methyl and optionally substituted phenyl; wherein X is -C(0)-NH-; wherein R is selected from substituted or unsubstituted 4-pyridyl, 3-

25

pyridyl, 2-pyridyl, triazolyl, 4-pyrimidinyl, 4-pyridazinyl, optionally substituted (heterocyclyl-substituted phenyl), 5-indazolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, indolyl, isoindolyl, benzotriazolyl, 2,3-dihydrobenzofuryl, 2-oxo-

- 1,2-dihydroquinol-7-yl, quinozalinyl, 4-isoquinolyl, 5-isoquinolyl, naphthyridinyl and 6-isoquinolyl; wherein substituted R is substituted with one or more substituents independently selected from chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, amino, dimethylamino, diethylamino, 1-
- 10 methylpiperidinylmethoxy, aminosulfonyl, cyclohexyl, dimethylaminopropynyl, dimethylaminoethoxy, 3-(4-morpholinyl)propyn-1-yl, dimethylaminoethoxyethoxy, optionally substituted piperidinyl, morpholinyl, optionally substituted piperazinyl, optionally substituted phenyl,
- methyl, ethyl, propyl, cyano, hydroxymethyl, aminomethyl, nitro and trifluoromethyl; wherein R¹ is selected from substituted or unsubstituted phenyl, indanyl, tetrahydronaphthyl, naphthyl, indazolyl, indolyl, 2,1,3benzothiadiazolyl, cyclohexyl, isoxazolyl, pyrazolyl,
- thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, isoindolyl, 2,3-dihydro-1H-indolyl, naphthyridinyl, benzothienyl, benzofuryl, benzimidazolyl, dihydro-benzimidazolyl, benzoxazolyl, benzthiazolyl,
- isoquinolyl, quinolyl, tetrahydroquinolyl, benzo[d]isothiazolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, benzodioxanyl and quinazolinyl; wherein substituted R¹ is substituted with one or more substituents independently
- selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl,

piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-

- piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, pyrrolidin-2-ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-
- pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
 pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl,
 methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl,
 aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3-
- ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1-methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl), imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tert-
- butyl, sec-butyl, trifluoromethyl, pentafluoroethyl,
 nonafluorobutyl, dimethylaminopropyl, 1,1di(trifluoromethyl)-1-hydroxymethyl, 1,1di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1-
- hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-
- ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; and wherein R² is one or more substituents independently selected from H, chloro, fluoro, bromo,

hydroxy, methoxy, ethoxy, trifluoromethoxy, oxo, amino, dimethylamino, aminosulfonyl, carboxymethyl, cyclopropyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, nitro, propenyl, propynyl and trifluoromethyl and unsubstituted or substituted heteroaryl selected from thienyl, furanyl, pyridyl, imidazolyl, and pyrazolyl; and pharmaceutically acceptable derivatives thereof.

8. Compound of Claim 6 wherein A is selected from

wherein R^c is selected from H, methyl and optionally substituted phenyl; wherein X is -C(0)-NH-; wherein R is selected from substituted or unsubstituted 4-pyridyl, 3-15 pyridyl, 2-pyridyl, triazolyl, 4-pyrimidinyl, 4-pyridazinyl, optionally substituted (heterocyclyl-substituted phenyl), 5indazolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, indolyl, isoindolyl, benzotriazolyl, 2,3-dihydrobenzofuryl, 2-oxo-1,2-dihydroquinol-7-yl, quinozalinyl, 4-isoquinolyl, 5-20 isoquinoly1, naphthyridiny1 and 6-isoquinoly1; wherein substituted R is substituted with one or more substituents independently selected from chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, amino, dimethylamino, diethylamino, 1methylpiperidinylmethoxy, aminosulfonyl, cyclohexyl, 25 dimethylaminopropynyl, dimethylaminoethoxy, 3-(4morpholinyl)propyn-1-yl, dimethylaminoethoxyethoxy, optionally substituted piperidinyl, morpholinyl, optionally

substituted piperazinyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, aminomethyl, nitro and trifluoromethyl; wherein \mathbb{R}^1 is selected from substituted or unsubstituted phenyl, indanyl,

- tetrahydronaphthyl, naphthyl, indazolyl, indolyl, 2,1,3-benzothiadiazolyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, isoindolyl, 2,3-dihydro-1H-indolyl,
- naphthyridinyl, benzothienyl, benzofuryl, benzimidazolyl, dihydro-benzimidazolyl, benzoxazolyl, benzthiazolyl, isoquinolyl, quinolyl, tetrahydroquinolyl, benzo[d]isothiazolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl,
- benzodioxanyl and quinazolinyl; wherein substituted R¹ is substituted with one or more substituents independently selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl,
- phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-
- Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl,
- pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Bocpyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
 pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl,
 methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl,

aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl),

- imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1di(trifluoromethyl)-1-hydroxymethyl, 1,1-
- di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(Nisopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy,
- phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy,
 pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1 ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol 2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4 ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and
 ethoxy; and wherein R² is one or more substituents
- independently selected from H, chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, trifluoromethoxy, oxo, amino, dimethylamino, aminosulfonyl, carboxymethyl, cyclopropyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano,
- hydroxymethyl, nitro, propenyl, propynyl and trifluoromethyl and unsubstituted or substituted heteroaryl selected from thienyl, furanyl, pyridyl, imidazolyl, and pyrazolyl; and pharmaceutically acceptable derivatives thereof.
- 30 9. Compound of Claim 6 wherein A is selected from

$$\int_{\mathbb{S}}$$
 , $\int_{\mathbb{R}^c}$, $\int_{\mathbb{R}^c}$ and $\int_{\mathbb{N}}$

wherein R^c is selected from H, methyl and optionally substituted phenyl; wherein X is -C(0)-NH-; wherein R is selected from substituted or unsubstituted 4-pyridyl, 3-

- pyridyl, 2-pyridyl, triazolyl, 4-pyrimidinyl, 4-pyridazinyl, optionally substituted (heterocyclyl-substituted phenyl), 5-indazolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, indolyl, isoindolyl, benzotriazolyl, 2,3-dihydrobenzofuryl, 2-oxo-1,2-dihydroquinol-7-yl, quinozalinyl, 4-isoquinolyl, 5-
- isoquinolyl, naphthyridinyl and 6-isoquinolyl; wherein substituted R is substituted with one or more substituents independently selected from chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, amino, dimethylamino, diethylamino, 1-methylpiperidinylmethoxy, aminosulfonyl, cyclohexyl,
- dimethylaminopropynyl, dimethylaminoethoxy, 3-(4morpholinyl)propyn-1-yl, dimethylaminoethoxyethoxy,
 optionally substituted piperidinyl, morpholinyl, optionally
 substituted piperazinyl, optionally substituted phenyl,
 methyl, ethyl, propyl, cyano, hydroxymethyl, aminomethyl,
- 20 nitro and trifluoromethyl; wherein R¹ is selected from substituted or unsubstituted phenyl, indanyl, tetrahydronaphthyl, naphthyl, indazolyl, indolyl, 2,1,3benzothiadiazolyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl,
- 25 pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, isoindolyl, 2,3-dihydro-1H-indolyl,
 naphthyridinyl, benzothienyl, benzofuryl, benzimidazolyl,
 dihydro-benzimidazolyl, benzoxazolyl, benzthiazolyl,
 isoquinolyl, quinolyl, tetrahydroquinolyl,
- benzo[d]isothiazolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, benzodioxanyl and quinazolinyl; wherein substituted R¹ is substituted with one or more substituents independently selected from bromo, chloro, fluoro, iodo, nitro, amino,

cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo,
aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl,
phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl,

- 5 piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2methyl-2-(1-methylpiperidin-4-yl) ethyl, morpholinylethyl, 1(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Bocpiperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-
- 4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl,
 pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl,
 pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Bocpyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
- pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl,
 methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl,
 aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-
- 20 methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl),
 imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl,
 hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, sec-butyl, trifluoromethyl, pentafluoroethyl,
- 25 nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1,1-di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1-hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-
- aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-

2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; and wherein R² is one or more substituents independently selected from H, chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, trifluoromethoxy, oxo, amino, dimethylamino, aminosulfonyl, carboxymethyl, cyclopropyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, nitro, propenyl, propynyl and trifluoromethyl and unsubstituted or substituted heteroaryl selected from thienyl, furanyl, pyridyl, imidazolyl, and pyrazolyl; and pharmaceutically acceptable derivatives thereof.

10. Compound of Claim 1, wherein A is selected from

15

20

25

10

wherein X is selected from

wherein R is selected from substituted or unsubstituted pyrazolyl, triazolyl, pyridyl, pyrimidinyl, and pyridazinyl, substituted phenyl, indazolyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, benzotriazolyl, 2,3-dihydrobenzofuryl, 2-oxo-1,2-dihydroquinol-7-yl, naphthyridinyl and quinazolinyl; wherein substituted R is substituted with one or more substituents independently selected from halo, hydroxy, C₁₋₄-alkyl, C₁₋₂-alkoxy,

optionally substituted 4-6 membered heterocyclyl- C_{1-2} -alkoxy, amino, C_{1-2} -alkylamino, aminosulfonyl, -NR 3 C(0)OR 3 , -NR 3 C(0)R 3 , C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, nitro,

- C_{1-2} -alkylamino- C_{1-2} -alkoxy- C_{1-2} -alkoxy, cyano, C_{1-2} -alkylamino- C_{1-2} -alkoxy, C_{1-2} -alkylamino- C_{1-2} -alkylamino- C_{2-3} -alkynyl, C_{1-2} -hydroxyalkyl, C_{1-2} -aminoalkyl, C_{1-2} -haloalkyl, optionally substituted 4-6 membered heterocyclyl- C_{2-3} -alkenyl, and optionally substituted 4-6 membered
- heterocyclyl-C₂₋₃-alkynyl; wherein R¹ is selected from substituted or unsubstituted aryl selected from phenyl, naphthyl, indanyl, indenyl and tetrahydronaphthyl, substituted or unsubstituted 5-6 membered heteroaryl, C₃₋₆-cycloalkyl, and substituted or unsubstituted 9-10 membered
- bicyclic or 13-14 membered tricyclic heterocyclyl; wherein substituted R^1 is substituted with one or more substituents independently selected from halo, C_{1-6} -alkyl, optionally substituted C_{3-6} -cycloalkyl, optionally substituted phenyl, optionally substituted phenyl- $C_{1-}C_{4}$ -alkylenyl, C_{1-2} -
- haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-C₁₋C₄-alkylenyl, optionally substituted 4-6 membered heterocyclyl-C₂₋C₄-alkenylenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered
- heterocyclyloxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl-C₁₋₄-alkylcarbonyl, C₁₋₂-haloalkyl, C₁₋₄-
- aminoalkyl, nitro, amino, hydroxy, cyano, aminosulfonyl, C_{1-2} -alkylsulfonyl, halosulfonyl, C_{1-4} -alkylcarbonyl, C_{1-3} -alkylamino- C_{1-3} -alkyl, C_{1-3} -alkylamino- C_{1-3} -alkoxy- C_{1-3} -alkoxy, C_{1-4} -alkoxycarbonyl, C_{1-4} -

alkoxycarbonylamino- C_{1-4} -alkyl, C_{1-4} -hydroxyalkyl, and C_{1-4} -alkoxy; wherein R^2 is one or more substituents independently selected from H, halo, hydroxy, C_{1-2} -alkoxy, C_{1-2} -haloalkoxy, amino, C_{1-2} -alkylamino, optionally substituted 4-6 membered heterocyclyl- C_{1-2} -alkylamino, 5 aminosulfonyl, C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, C_{1-4} alkyl, cyano, C_{1-2} -hydroxyalkyl, C_{1-3} -carboxyalkyl, nitro, C_{2-} $_3\text{-alkenyl},\ C_{2\text{-}3}\text{-alkynyl}$ and $C_{1\text{-}2}\text{-haloalkyl};$ wherein R^3 is independently selected from H, C_{1-4} -alkyl, optionally 10 substituted phenyl, optionally substituted phenyl- C_{1-4} -alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C₁₋₄-alkyl, optionally substituted C_3-C_6 cycloalkyl and C_{1-2} -haloalkyl; wherein R^{4a} is C_{2-3} -alkylenyl where one of the CH_2 groups may be replaced 15 with an oxygen atom or an -NH-, wherein R^{4a} is optionally substituted with hydroxy; wherein R^5 is selected from H and C_{1-2} -alkyl; wherein R^{5a} is selected from H and C_{1-2} -alkyl; wherein R^e and R^f are independently selected from H and C_{1-2} haloalkyl; and wherein R^7 is selected from H, C_{1-3} -alkyl, 20 optionally substituted phenyl, optionally substituted phenyl- C_{1-3} -alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- $C_{1-}C_{3}$ -alkyl, C_{1-3} -alkoxy- C_{1-2} -alkyl and C_{1-3} alkoxy- C_{1-3} -alkoxy- C_{1-3} -alkyl, and pharmaceutically acceptable 25

derivatives thereof.

; wherein X is -C(0)-NH-; wherein R is selected

from substituted or unsubstituted 4-pyridyl, 3-pyridyl, 2-pyridyl, triazolyl, 4-pyrimidinyl, 4-pyridazinyl, optionally substituted (heterocyclyl-substituted phenyl), 5-indazolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, indolyl, isoindolyl,

- benzotriazoly1, 2,3-dihydrobenzofury1, 2-oxo-1,2-dihydroquinol-7-yl, quinozaliny1, 4-isoquinoly1, 5-isoquinoly1, naphthyridiny1 and 6-isoquinoly1; wherein substituted R is substituted with one or more substituents independently selected from chloro, fluoro, bromo, hydroxy,
- methoxy, ethoxy, amino, dimethylamino, diethylamino, 1methylpiperidinylmethoxy, aminosulfonyl, cyclohexyl, dimethylaminopropynyl, dimethylaminoethoxy, 3-(4morpholinyl)propyn-1-yl, dimethylaminoethoxyethoxy, optionally substituted piperidinyl, morpholinyl, optionally
- substituted piperazinyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, aminomethyl, nitro and trifluoromethyl; wherein R¹ is selected from substituted or unsubstituted phenyl, indanyl, tetrahydronaphthyl, naphthyl, indazolyl, indolyl, 2,1,3-
- benzothiadiazolyl, cyclohexyl, isoxazolyl, pyrazolyl,
 thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl,
 pyridazinyl, 2-oxo-1,2-dihydroquinol-7-yl, 1,2,3,4tetrahydro-isoquinolyl, isoindolyl, 2,3-dihydro-1H-indolyl,
 naphthyridinyl, benzothienyl, benzofuryl, benzimidazolyl,
- dihydro-benzimidazolyl, benzoxazolyl, benzthiazolyl, isoquinolyl, quinolyl, tetrahydroquinolyl, benzo[d]isothiazolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, benzodioxanyl and quinazolinyl; wherein substituted R¹ is
- substituted with one or more substituents independently selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-

4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-

- Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl,
- pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Bocpyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
 pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl,
 methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl,
- aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl), imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl,
- 20 hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1,1-di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-
- di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(Nisopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy,
 phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy,
- pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; and wherein R² is one or more substituents

20

25

30

independently selected from H, chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, trifluoromethoxy, oxo, amino, dimethylamino, aminosulfonyl, carboxymethyl, cyclopropyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, nitro, propenyl, propynyl, trifluoromethyl and unsubstituted or substituted heteroaryl selected from thienyl, furanyl, pyridyl, imidazolyl, and pyrazolyl; and pharmaceutically acceptable derivatives thereof.

10 12. Compound of Claim 1 wherein A is 9- or 10-membered fused partially saturated heterocyclyl or 9- or 10-membered fused heteroaryl; wherein X is selected from

$$\begin{array}{c|c}
 & O \\
 & N \\$$

wherein R is selected from substituted or unsubstituted 5-6 membered heteroaryl comprising one or more nitrogen atoms, substituted phenyl and substituted or unsubstituted 9-10 membered bicyclic or 13-14 membered tricyclic heterocyclyl; wherein substituted R is substituted with one or more substituents independently selected from $\texttt{halo, -OR}^3, -\texttt{SR}^3, -\texttt{SO}_2\texttt{R}^3, -\texttt{CO}_2\texttt{R}^3, -\texttt{CONR}^3\texttt{R}^3, -\texttt{COR}^3, -\texttt{NR}^3\texttt{R}^3, -\texttt{NR$ $SO_2NR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)R^3$, C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, nitro, C_{1-4} -alkylamino- C_{1-4} -alkoxy- C_{1-4} alkoxy, cyano, C_{1-4} -alkylamino- C_{1-4} -alkoxy, C_{1-2} -alkyl substituted with R^2 , C_{2-3} -alkenyl substituted with R^2 , and C_{2-3} $_3$ -alkynyl substituted with ${\ensuremath{R}}^2\,;$ wherein ${\ensuremath{R}}^1$ is selected from substituted or unsubstituted aryl selected from phenyl, naphthyl, indanyl, indenyl and tetrahydronaphthyl, substituted or unsubstituted 5-6 membered heteroaryl, C_{3-6} cycloalkyl, and substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl; wherein substituted $\ensuremath{\mathbb{R}}^1$

is substituted with one or more substituents independently selected from halo, $-OR^3$, oxo, $-SR^3$, $-SO_2R^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-NH(C_1-C_4$ alkylenyl R^3), $-(C_1-C_4$ alkylenyl)NR $^3R^3$, $-SO_2NR^3R^3$, $-NR^3C(0)OR^3$, $-NR^3C(0)R^3$, C_1-C_6 -alkylamino- C_1-C_6 -alkoxy, C_1-C_6 -alkylamino- C_1-C_6 -alkoxy, halosulfonyl, optionally substituted 4-6 membered heterocyclylcarbonylalkyl, C_{1-4} -alkoxycarbonylamino- C_{1-6} -

optionally substituted C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, optionally substituted phenyl- $C_{1\text{-}6}$ -10 alkylenyl, optionally substituted 4-6 membered heterocyclyl- C_1 - C_6 -alkylenyl, 4-6 membered heterocyclyl- C_2 - C_6 -alkenylenyl, C_{1-6} -alkyl, cyano, C_{1-4} -hydroxyalkyl, nitro and C_{1-4} -haloalkyl; wherein R2 is one or more substituents independently selected from H, halo, $-OR^3$, oxo, $-SR^3$, $-CO_2R^3$, $-CONR^3R^3$, -15 COR^3 , $-NR^3R^3$, $-SO_2NR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)R^3$, C_{3-6} cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, C_{1-6} -alkyl, cyano, C_{1-4} -hydroxyalkyl, C_{1-4} -carboxyalkyl, nitro, C_{2-3} alkenyl, C_{2-3} -alkynyl and C_{1-4} -haloalkyl; wherein R^3 is 20 independently selected from H, C_{1-4} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-4} -alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C₁₋₄-alkyl, optionally substituted C_3 - C_6 cycloalkyl and C_{1-2} -haloalkyl; wherein R^{4a} 25 is C_{2-4} -alkylenyl, where one of the CH_2 groups may be replaced with an oxygen atom or an -NH-; wherein R^{4a} is optionally substituted with hydroxy; wherein R5 is selected from H and C_{1-2} -alkyl; wherein R^{5a} is selected from H and C_{1-2} alkyl; wherein \boldsymbol{R}^{e} and \boldsymbol{R}^{f} are independently selected from \boldsymbol{H} 30 and C_{1-2} -haloalkyl; and wherein R^7 is selected from H, C_{1-6} alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-6} -alkyl, optionally substituted 4-6 membered

heterocyclyl, optionally substituted 4-6 membered heterocyclyl- $C_{1-}C_{6}$ -alkyl, C_{1-4} -alkoxy- C_{1-4} -alkyl and C_{1-4} -alkoxy- C_{1-4} -alkoxy- C_{1-4} -alkyl, and pharmaceutically acceptable derivatives thereof.

5

10

13. Compound of Claim 12 wherein A is selected from benzothienyl, benzofuryl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, indolyl, isoindolyl, quinolyl, isoquinolyl, naphthpyridinyl, tetrahydroquinolyl, quinoxalinyl and quinazolinyl; and pharmaceutically acceptable salts thereof.

14. Compound of Claim 1, wherein A is 5- or 6-membered cycloalkenyl; wherein X is selected from

15

wherein R is selected from substituted or unsubstituted 5-6 membered heteroaryl comprising one or more nitrogen atoms, substituted phenyl and substituted or unsubstituted 9-10 membered bicyclic or 13-14 membered 20 tricyclic heterocyclyl; wherein substituted R is substituted with one or more substituents independently selected from halo, $-OR^3$, $-SR^3$, $-SO_2R^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, - $SO_2NR^3R^3$, $-NR^3C(0)OR^3$, $-NR^3C(0)R^3$, C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally 25 substituted phenyl, nitro, C_{1-4} -alkylamino- C_{1-4} -alkoxy- C_{1-4} alkoxy, cyano, C_{1-4} -alkylamino- C_{1-4} -alkoxy, C_{1-2} -alkyl substituted with R^2 , C_{2-3} -alkenyl substituted with R^2 , and C_{2-1} $_3$ -alkynyl substituted with R^2 ; wherein R^1 is selected from substituted or unsubstituted aryl selected from phenyl, 30 naphthyl, indanyl, indenyl and tetrahydronaphthyl, substituted or unsubstituted 5-6 membered heteroaryl, C_{3-6} -

cycloalkyl, and substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl; wherein substituted R^1 is substituted with one or more substituents independently selected from halo, $-OR^3$, oxo, $-SR^3$, $-SO_2R^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-NH(C_1-C_4$ alkylenyl R^3), $-(C_1-C_4$ alkylenyl)NR $^3R^3$, $-SO_2NR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)R^3$, C_1-C_6 -alkylamino- C_1-C_6 -alkoxy, halosulfonyl, optionally substituted 4-6 membered heterocyclylcarbonylalkyl, C_{1-4} -alkoxycarbonylamino- C_{1-6} -

alkyl, R^7 , optionally substituted C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-6} -alkylenyl, optionally substituted 4-6 membered heterocyclyl- C_{1-C_6} -alkylenyl, 4-6 membered heterocyclyl- C_{2-C_6} -alkenylenyl,

15 C_{1-4} -alkyl, cyano, C_{1-4} -hydroxyalkyl, nitro and C_{1-4} -haloalkyl; wherein R^2 is one or more substituents independently selected from H, halo, $-OR^3$, oxo, $-SR^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-SO_2NR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)R^3$, C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally

substituted phenyl, C_{1-6} -alkyl, cyano, C_{1-4} -hydroxyalkyl, C_{1-4} -carboxyalkyl, nitro, C_{2-3} -alkenyl, C_{2-3} -alkynyl and C_{1-4} -haloalkyl; wherein R^3 is independently selected from H, C_{1-4} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-4} -alkyl, optionally substituted 4-6 membered

25 heterocyclyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkyl, optionally substituted C_3 - C_6 cycloalkyl and C_{1-2} -haloalkyl; wherein R^{4a} is C_{2-4} -alkylenyl, where one of the CH₂ groups may be replaced with an oxygen atom or an -NH-; wherein R^{4a} is optionally substituted with

30 hydroxy; wherein R^5 is selected from H and C_{1-2} -alkyl; wherein R^{5a} is selected from H and C_{1-2} -alkyl; wherein R^{e} and R^{f} are independently selected from H and C_{1-2} -haloalkyl; and wherein R^7 is selected from H, C_{1-6} -alkyl, optionally substituted

phenyl, optionally substituted phenyl- C_{1-6} -alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- $C_{1-}C_{6}$ -alkyl, C_{1-4} -alkoxy- C_{1-4} -alkyl and C_{1-4} -alkoxy- C_{1-4} -alkoxy- C_{1-4} -alkyl, and pharmaceutically acceptable derivatives thereof.

15. Compound of Claim 1, wherein A is phenyl; wherein ${\tt X}$ is selected from

$$\begin{array}{c|c}
 & O \\
 & N \\
 & N \\
 & R^{5a}
\end{array}$$
and
$$\begin{array}{c}
 & N \\
 & R^{5a}
\end{array}$$

wherein R is selected from substituted or 10 unsubstituted 5-6 membered heteroaryl comprising one or more nitrogen atoms, substituted phenyl and substituted or unsubstituted 9-10 membered bicyclic or 13-14 membered tricyclic heterocyclyl; wherein substituted R is substituted 15 with one or more substituents independently selected from $\label{eq:halo_equation} \text{halo, } -\text{OR}^3\,, \ -\text{SR}^3\,, \ -\text{SO}_2\text{R}^3\,, \ -\text{CO}_2\text{R}^3\,, \ -\text{COR}^3\text{R}^3\,, \ -\text{COR}^3\,, \ -\text{NR}^3\text{R}^3\,, \ -\text{COR}^3\,, \ -\text{COR}^3\,, \ -\text{NR}^3\text{R}^3\,, \ -\text{COR}^3\,, \ -\text{NR}^3\text{R}^3\,, \ -\text{COR}^3\,, \ -\text{NR}^3\text{R}^3\,, \ -\text{COR}^3\,, \ -\text{COR}^3\,, \ -\text$ $SO_2NR^3R^3$, $-NR^3C(0)OR^3$, $-NR^3C(0)R^3$, C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, nitro, $C_{1\text{--}4}$ -alkylamino- $C_{1\text{--}4}$ -alkoxy- $C_{1\text{--}4}$ -20 alkoxy, cyano, C_{1-4} -alkylamino- C_{1-4} -alkoxy, C_{1-2} -alkyl substituted with R^2 , C_{2-3} -alkenyl substituted with R^2 , and C_{2-3} $_3$ -alkynyl substituted with ${
m R}^2$; wherein ${
m R}^1$ is selected from substituted or unsubstituted aryl selected from phenyl, naphthyl, indanyl, indenyl and tetrahydronaphthyl, 25 substituted or unsubstituted 5-6 membered heteroaryl, C_{3-6} cycloalkyl, and substituted or unsubstituted 9-14 membered

substituted or unsubstituted 5-6 membered neteroary1, C₃₋₆-cycloalkyl, and substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl; wherein substituted R¹ is substituted with one or more substituents independently selected from halo, -OR³, oxo, -SR³, -SO₂R³, -CO₂R³, -CONR³R³, -CONR³R³, -NH(C₁-C₄ alkylenylR³), -(C₁-C₄ alkylenyl)NR³R³, -SO₂NR³R³, -NR³C(O)OR³, -NR³C(O)R³, C₁-C₆-alkylamino-C₁-C₆-

alkoxy, C_1 - C_6 -alkylamino- C_1 - C_6 -alkoxy- C_1 - C_6 -alkoxy, halosulfonyl, optionally substituted 4-6 membered heterocyclylcarbonylalkyl, C_{1-4} -alkoxycarbonylamino- C_{1-6} -

alkyl, $R^{e} \longrightarrow R^{f}$, optionally substituted C_{3-6} -cycloalkyl,

optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-6} -alkylenyl, optionally substituted 4-6 membered heterocyclyl- $C_{1-}C_{6}$ -alkylenyl, 4-6 membered heterocyclyl- $C_{2-}C_{6}$ -alkenylenyl, C_{1-6} -alkyl, cyano, C_{1-4} -hydroxyalkyl, nitro and C_{1-4} -haloalkyl;

wherein R^2 is one or more substituents independently selected from H, halo, $-OR^3$, oxo, $-SR^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-SO_2NR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)R^3$, C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, C_{1-6} -alkyl, cyano, C_{1-4} -hydroxyalkyl, C_{1-4} -

15 carboxyalkyl, nitro, C_{2-3} -alkenyl, C_{2-3} -alkynyl and C_{1-4} -haloalkyl; wherein R^3 is independently selected from H, C_{1-4} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-4} -alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered

20 heterocyclyl- C_{1-4} -alkyl, optionally substituted C_3 - C_6 cycloalkyl and C_{1-2} -haloalkyl; wherein R^{4a} is C_{2-4} -alkylenyl, where one of the CH_2 groups may be replaced with an oxygen atom or an -NH-; wherein R^{4a} is optionally substituted with hydroxy; wherein R^5 is selected from H and C_{1-2} -alkyl; wherein

25 R^{5a} is selected from H and C_{1-2} -alkyl; wherein R^e and R^f are independently selected from H and C_{1-2} -haloalkyl; and wherein R^7 is selected from H, C_{1-6} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-6} -alkyl, optionally substituted 4-6 membered heterocyclyl, optionally

30 substituted 4-6 membered heterocyclyl- $C_{1-}C_{6}$ -alkyl, C_{1-4} -alkoxy- C_{1-4} -alkyl and C_{1-4} -alkoxy- C_{1-4} -alkoxy- C_{1-4} -alkyl, and pharmaceutically acceptable derivatives thereof.

- 16. Compound of Claim 1 and pharmaceutically
- acceptable salts thereof selected from
- N-(4-Chlorophenyl)[2-(6-quinolylamino)(3pyridyl)]carboxamide;
- 5 N-(4-Chlorophenyl)[2-(5-isoquinolylamino)(3-pyridyl)]carboxamide;
 - N-(4-Chlorophenyl) [2-(1H-indazol-5-ylamino) (3-pyridyl)] carboxamide;
 - N-(4-Chlorophenyl) [2-(1H-indazol-6-ylamino)(3-
- 10 pyridyl)]carboxamide;
 - 2-(1H-Indazol-6-ylamino)-N-(4-isopropyl-phenyl)nicotinamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[3(methylethyl)phenyl]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[4-
- 15 (methylpropyl)phenyl]carboxamide;
 - N-[4-(tert-Butyl)phenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[3-(trifluoromethyl)phenyl]carboxamide;
- 20 N-[3-(tert-Butyl)phenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - [2-(Benzotriazol-6-ylamino)(3-pyridyl)]-N-[4-(tert-butyl)phenyl]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-(3-phenylpyrazol-5-yl)carboxamide;
 - N-(4-Chloro-3-sulfamoylphenyl)[2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-(4-methyl-2-oxo-1,2-dihydroquinol-7-yl)carboxamide;
- 30 N-[4-(Methylethyl)phenyl]{2-[(4-methyl-2-oxo(7-hydroquinolyl))amino](3-pyridyl)}carboxamide;
 - N-[5-(tert-Butyl)isoxazol-3-yl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;

- N-[5-(tert-Butyl)-1-methylpyrazol-3-yl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
- N-[4-(tert-Butyl)(1,3-thiazol-2-yl)][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
- 5 N-[5-(tert-Butyl)(1,3,4-thiadiazol-2-yl)][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[4(1,1,2,2,3,3,4,4,4-nonafluorobutyl)phenyl]carboxamide;
 - {2-[(1-Methyl(1H-indazol-6-yl))amino](3-pyridyl)}-N-[4-(methylethyl)phenyl]carboxamide;
- N-[4-(tert-Butyl)phenyl]{2-[(7-bromo(1H-indazol-6-yl))amino](3-pyridyl)}carboxamide;
 - 2-(1*H*-Indazol-6-ylamino)-*N*-[4-tert-butyl-3-(1,2,3,6-tetrahydropyridin-4-yl)phenyl]nicotinamide;
- 15 [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-
 - {4-[2,2,2-trifluoro-1-hydroxy-1 (trifluoromethyl)ethyl]phenyl}carboxamide;
 - N-[5-(tert-Butyl)-2-methoxyphenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
- - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-(1-oxo(7-2,3,4-trihydroisoquinolyl))carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[4-(methylethoxy)phenyl]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}carboxamide;
 - N-(4-{(1S)-1-[(Methylethyl)amino]ethyl)phenyl)[2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
- N-[4-(tert-Butyl)-3-(4-methylpiperazinyl)phenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[3-(4methylpiperazinyl)phenyl]carboxamide;

- N-[4-(tert-Butyl)-2-(4-methylpiperazinyl)phenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
- N-{2-[2-(Dimethylamino)ethoxy]-5-(tert-butyl)phenyl}[2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
- 5 N-{3-[2-(Dimethylamino)ethoxy]phenyl}[2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - N-(3-Hydroxy-4-methoxyphenyl)[2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - N-{3-[2-(Dimethylamino)ethoxy]-4-methoxyphenyl}[2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[4-methoxy-3-(1-methyl(4-piperidyl)oxy)phenyl]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-(5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolin-2-yl)carboxamide;
- 15 [2-({3-[2-(Dimethylamino)ethoxy](1H-indazol-6-yl)}amino)(3pyridyl)]-N-[4-(tert-butyl)phenyl]carboxamide;
 - N-[3,3-Dimethyl-1-(4-piperidylmethyl)] indolin-6-yl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
- N-[3,3-Dimethyl-1-(1-methyl-piperidin-4-ylmethyl)-2,3dihydro-1H-indol-6-yl]-2-(1H-indazol-6-ylamino)nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-(4-phenoxy-phenyl)-nicotinamide;
 - [2-(1H-Indazol-5-ylamino)(3-pyridyl)]-N-(4-phenoxyphenyl)carboxamide;
- 25 [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-(4phenylphenyl)carboxamide;
 - [2-(1H-indazol-6-ylamino)(3-pyridyl)]-N-[4(methylsulfonyl)phenyl]carboxamide;
- [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[1-(1-methyl(4-30 piperidyl))indolin-6-yl]carboxamide;
 - N-[3,3-Dimethyl-1-(1-methyl(4-piperidyl))indolin-6-yl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[3-(1-methyl(4piperidyl))indol-5-yl]carboxamide;

- [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[4(trifluoromethyl)phenyl]carboxamide;
- N-{3-[3-(Dimethylamino)propyl]-5-(trifluoromethyl)phenyl}[2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
- 5 [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[5-(1-methyl(4-1,2,5,6-tetrahydropyridyl))-3-(trifluoromethyl)phenyl]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[4-(1-methyl(4-piperidyl))phenyl]carboxamide;
- 10 N-[4-(tert-Butyl)-3-(3-piperidylpropyl)phenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - N-[3-((1E)-4-Pyrrolidinylbut-1-enyl)-4-(tert-butyl)phenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
- 15 N-[4-(tert-Butyl)-3-(3-pyrrolidinylpropyl)phenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - N-[4-(tert-Butyl)-3-(3-morpholin-4-ylpropyl)phenyl][2-(1H-indazol-6-ylamino)(3-pyridyl)]carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-{3-[3-(4-
- 20 methylpiperazinyl)-3-oxopropyl]phenyl}carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-{4-[3-(4-methylpiperazinyl)-3-oxopropyl]phenyl}carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-{3-[3-(4-methylpiperazinyl)propyl]phenyl}carboxamide;
- 25 [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-{4-[3-(4methylpiperazinyl)propyl]phenyl}carboxamide;
 - [2-(1H-Indazol-6-ylamino)(3-pyridyl)]-N-[1-(2-morpholin-4-ylethyl)indol-6-yl]carboxamide;
- N-[4-(1,1-Dimethyl-3-morpholin-4-ylpropyl)phenyl][2-(1Hindazol-6-ylamino)(3-pyridyl)]carboxamide;
 - 2-(1H-Indazol-6-ylamino)-N-(4-{2,2,2-trifluoro-1-[2-(2-methoxy-ethoxy)-ethoxy]-1-trifluoromethyl-ethyl}-phenyl)-nicotinamide;

17. A compound of Claim 1 having Formula II

(trifluoromethyl)phenyl]carboxamide.

15

wherein R is selected from unsubstituted or substituted 9or 10-membered fused nitrogen-containing heteroaryl,
wherein R is substituted with one or more substituents
selected from halo, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-haloalkyl, C₁₋₆-alkoxy, optionally substituted
heterocyclylalkoxy, C₁₋₆-alkylamino-C₂₋₄-alkynyl,
C₁₋₆-alkylamino-C₁₋₆-alkoxy, C₁₋₆-alkylamino-C₁₋₆alkoxy-C₁₋₆-alkoxy, and optionally substituted
heterocyclyl-C₂₋₄-alkynyl;
wherein R¹ is selected from unsubstituted or substituted
aryl,

aryl, cycloalkyl, 5-6 membered heteroaryl and 9-10 membered bicyclic and 13-14 membered tricyclic heterocyclyl,

wherein substituted R1 is substituted with one or more substituents selected from halo, C₁₋₆-alkyl, optionally 5 substituted C3-6-cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-C₁₋C₄-alkylenyl, C₁₋₂-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-C1.C4alkyl, optionally substituted 4-6 membered 10 heterocyclyl-C2-C4-alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, 15 optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkylcarbonyl, C_{1-2} haloalkyl, C_{1-4} -aminoalkyl, nitro, amino, hydroxy, 20 cyano, aminosulfonyl, C_{1-2} -alkylsulfonyl, halosulfonyl, C_{1-4} -alkylcarbonyl, C_{1-3} -alkylamino- C_{1-3} -alkyl, C_{1-3} alkylamino- C_{1-3} -alkoxy, C_{1-3} -alkylamino- C_{1-3} -alkoxy- C_{1-3} alkoxy, C_{1-4} -alkoxycarbonyl, C_{1-4} -alkoxycarbonylamino- C_{1-4}

 R^{e} R^{f} R^{7} and C_{1-4} -hydroxyalkyl, R^{e} and R^{f}

25 wherein \mathbb{R}^2 is one or more substituents independently selected from

Η,

halo,

hydroxy,

30 amino,

 C_{1-6} -alkyl,

C₁₋₆-haloalkyl,

 C_{1-6} -alkoxy,

 C_{1-2} -alkylamino, aminosulfonyl, C_{3-6} -cycloalkyl, cyano,

5 C_{1-2} -hydroxyalkyl,

nitro,

 C_{2-3} -alkenyl,

 C_{2-3} -alkynyl,

 C_{1-6} -haloalkoxy,

10 C_{1-6} -carboxyalkyl,

4-6-membered heterocyclyl-C₁₋₆-alkylamino, unsubstituted or substituted phenyl and unsubstituted or substituted 4-6 membered heterocyclyl;

15 wherein R^4 is selected from a direct bond, C_{1-4} -alkyl, and

wherein R^e and R^f are independently selected from H and $C_{1\text{-}2}$ -haloalkyl; and

wherein R^7 is selected from H, C_{1-3} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-3} -alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- C_{1-} C3-alkyl, C_{1-3} -alkoxy- C_{1-2} -alkyl and C_{1-3} -alkoxy- C_{1-3} -alkoxy- C_{1-3} -alkyl; and pharmaceutically acceptable derivatives thereof.

25

18. Compound of Claim 17 wherein R is selected from indazolyl, where R is unsubstituted or substituted with one or more substituents selected from chloro, fluoro, amino, hydroxy, methyl, ethyl, propyl, trifluoromethyl,

dimethylaminopropynyl, 1-methylpiperdinylmethoxy, dimethylaminoethoxyethoxy, methoxy and ethoxy; wherein R¹ is selected from phenyl, tetrahydronaphthyl, indanyl, indenyl, naphthyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl,

thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, isoquinolyl, quinolyl, indolyl, isoindolyl, 2,3-dihydro-1H-indolyl, naphthyridinyl, quinozalinyl, benzo[d]isothiazolyl,

- 5 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, tetrahydroquinolinyl, indazolyl, 2,1,3-benzothiadiazolyl, benzodioxanyl, benzothienyl, benzofuryl, benzimidazolyl, dihydro-benzimidazolyl, benzoxazolyl and benzthiazolyl, where R¹ is
- unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-
- 4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-
- piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, pyrrolidin-2-ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-
- pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
 pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl,
 methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl,
 aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3-
- ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1-methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl), imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tert-

butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1,1-di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-

- di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(Nisopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy,
 phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy,
- pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; wherein R² is selected from H, chloro, fluoro,
- bromo, amino, hydroxy, methyl, ethyl, propyl, oxo,
 dimethylamino, aminosulfonyl, cyclopropyl, cyano,
 hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy,
 ethoxy, trifluoromethoxy, carboxymethyl,
 morpholinylethylamino, propynyl, unsubstituted or
- substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl,

furanyl, pyridyl, imidazolyl, and pyrazolyl; and wherein \mathbb{R}^4 is selected from a direct bond, ethyl, butyl, and

; and pharmaceutically acceptable derivatives

25 thereof.

19. A compound of Claim 1 having Formula III

10

III

wherein R is selected from unsubstituted or substituted 9or 10-membered fused nitrogen-containing heteroaryl,
where R is substituted with one or more substituents
selected from halo, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-haloalkyl, C₁₋₆-alkoxy, optionally substituted
heterocyclylalkoxy, C₁₋₆-alkylamino-C₂₋₄-alkynyl,
C₁₋₆-alkylamino-C₁₋₆-alkoxy, C₁₋₆-alkylamino-C₁₋₆alkoxy-C₁₋₆-alkoxy, and optionally substituted
heterocyclyl-C₂₋₄-alkynyl;

wherein $\ensuremath{\mbox{R}}^1$ is selected from unsubstituted or substituted aryl,

cycloalkyl,

5-6 membered heteroaryl and
9-10 membered bicyclic and 13-14 membered
tricyclic heterocyclyl,

wherein substituted R¹ is substituted with one or more substituents selected from halo, C₁₋₆-alkyl, optionally substituted phenyl, optionally substituted phenyl, optionally substituted phenyl-C₁₋C₄-alkylenyl, C₁₋₂-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-C₁₋C₄-alkylenyl, optionally substituted 4-6 membered heterocyclyl-C₂₋C₄-alkenylenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-C₁₋₄-alkoxy, optionally substituted 4-6 membered heterocyclyl-C₁₋₄-alkoxy, optionally substituted 4-6 membered heterocyclyl-C₁₋₄-alkoxy, optionally

optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl-C₁₋₄-alkylcarbonyl, C₁₋₂-5 haloalkyl, C₁₋₄-aminoalkyl, nitro, amino, hydroxy, cyano, aminosulfonyl, C₁₋₂-alkylsulfonyl, halosulfonyl, C₁₋₄-alkylcarbonyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkoxy-C₁₋₃-alkoxy, C₁₋₄-alkoxycarbonylamino-C₁₋₃-alkoxy-C₁₋₃-alkoxy, C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkoxycarbonylamino-C₁₋₄-alk

10 $_{4}$ -alkyl, C_{1-4} -hydroxyalkyl, $O^{R'}$ and C_{1-4} -alkoxy; wherein R^{2} is one or more substituents independently selected from

Η,

halo,

hydroxy,

amino,

 C_{1-6} -alkyl,

 C_{1-6} -haloalkyl,

 C_{1-6} -alkoxy,

 C_{1-2} -alkylamino,

aminosulfonyl,

 C_{3-6} -cycloalkyl,

cyano,

 C_{1-2} -hydroxyalkyl,

25 nitro,

 C_{2-3} -alkenyl,

 C_{2-3} -alkynyl,

 C_{1-6} -haloalkoxy,

 C_{1-6} -carboxyalkyl,

30 4-6-membered heterocyclyl-C₁₋₆-alkylamino, unsubstituted or substituted phenyl and unsubstituted or substituted 4-6 membered heterocyclyl; wherein R^4 is selected from a direct bond, C_{1-4} -alkyl, and

wherein R^e and R^f are independently selected from H and C_{1-2} -haloalkyl; and

- wherein R^7 is selected from H, C_{1-3} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-3} -alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- $C_{1-}C_{3}$ -alkyl, C_{1-3} -alkoxy- C_{1-2} -alkyl and C_{1-3} -alkoxy- C_{1-3} -alkoxy- C_{1-3} -alkyl; and pharmaceutically acceptable derivatives thereof.
 - 20. Compound of Claim 19 wherein R is selected from indazolyl, where R is unsubstituted or substituted with one or more substituents selected from chloro, fluoro, amino,
- hydroxy, methyl, ethyl, propyl, trifluoromethyl, dimethylaminopropynyl, 1-methylpiperdinylmethoxy, dimethylaminoethoxyethoxy, methoxy and ethoxy; wherein R¹ is selected from phenyl, tetrahydronaphthyl, indanyl, indenyl, naphthyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl,
- thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, isoquinolyl, quinolyl, indolyl, isoindolyl, 2,3-dihydro-1H-indolyl, naphthyridinyl, quinozalinyl, benzo[d]isothiazolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-
- 25 1,2,4-triazolo[3,4-a]isoquinolyl, tetrahydroquinolinyl, indazolyl, 2,1,3-benzothiadiazolyl, benzodioxanyl, benzothienyl, benzofuryl, dihydro-benzimidazolyl, benzimidazolyl, benzoxazolyl and benzthiazolyl, where R¹ is unsubstituted or substituted with one or more substituents
- selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-

4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-

- Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl,
- pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Bocpyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
 pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl,
 methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl,
- aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl), imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl,
- 20 hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, sec-butyl, trifluoromethyl, pentafluoroethyl,
 nonafluorobutyl, dimethylaminopropyl, 1,1di(trifluoromethyl)-1-hydroxymethyl, 1,1di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-
- di(trifluoromethyl)-1-(methoxyethoxyethoxy) methyl, 1hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1aminoethyl, 2-aminoethyl, 1-(N-isopropylamino) ethyl, 2-(Nisopropylamino) ethyl, dimethylaminoethoxy, 4-chlorophenoxy,
 phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy,
- pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; wherein R² is selected from H, chloro, fluoro,

bromo, amino, hydroxy, methyl, ethyl, propyl, oxo, dimethylamino, aminosulfonyl, cyclopropyl, cyano, hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl,

morpholinylethylamino, propynyl, unsubstituted or substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl,

furanyl, pyridyl, imidazolyl, and pyrazolyl; and wherein ${\bf R}^4$ is selected from a direct bond, ethyl, butyl, and

; and pharmaceutically acceptable derivatives thereof.

21. A compound of Claim 1 having Formula IV

$$R^{2} \xrightarrow{\stackrel{1}{\underset{}}} R^{4}$$

$$R^{3}$$

$$R^{3}$$

$$R^{4}$$

$$R^{1}$$

$$R$$

$$R$$

$$R$$

$$R$$

$$R$$

15

25

wherein A^3 is selected from CR^2 and N; wherein A^4 is selected from CR^2 and N; provided one of A^3 and A^4 is not CR^2 ;

wherein R is selected from unsubstituted or substituted 9- or 10-membered fused nitrogen-containing heteroaryl,

where R is substituted with one or more substituents selected from halo, amino, hydroxy, C_{1-6} -alkyl, C_{1-6} -alkoxy, optionally substituted heterocyclylalkoxy, C_{1-6} -alkylamino- C_{2-4} -alkynyl, C_{1-6} -alkylamino- C_{1-6} -alkoxy, C_{1-6} -alkylamino- C_{1-6} -

alkoxy- C_{1-6} -alkoxy, and optionally substituted heterocyclyl- C_{2-4} -alkynyl;

wherein R^1 is selected from unsubstituted or substituted aryl,

5 cycloalkyl,

5-6 membered heteroaryl and 9-10 membered bicyclic and 13-14 membered

tricyclic heterocyclyl,

wherein substituted R1 is substituted with one or more substituents selected from halo, C_{1-6} -alkyl, optionally 10 substituted C_{3-6} -cycloalkyl, optionally substituted phenyl, optionally substituted phenyl- C_1 - C_4 -alkylenyl, C_{1-2} -haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl- C_1 - C_4 alkylenyl, optionally substituted 4-6 membered 15 heterocyclyl- C_2 - C_4 -alkenylenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, 20 optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkylcarbonyl, C_{1-2} haloalkyl, C_{1-4} -aminoalkyl, nitro, amino, hydroxy, 25 cyano, aminosulfonyl, C1-2-alkylsulfonyl, halosulfonyl, C_{1-4} -alkylcarbonyl, C_{1-3} -alkylamino- C_{1-3} -alkyl, C_{1-3} alkylamino- C_{1-3} -alkoxy, C_{1-3} -alkylamino- C_{1-3} -alkoxy- C_{1-3} alkoxy, C_{1-4} -alkoxycarbonyl, C_{1-4} -alkoxycarbonylamino- C_{1-4}

30 $_{4}$ -alkyl, C_{1-4} -hydroxyalkyl, 0 7 and C_{1-4} -alkoxy; wherein R^{2} is one or more substituents independently selected from

halo,

hydroxy,

amino,

 C_{1-6} -alkyl,

5 C₁₋₆-haloalkyl,

 C_{1-6} -alkoxy,

 C_{1-2} -alkylamino,

aminosulfonyl,

 C_{3-6} -cycloalkyl,

10 cyano,

20

 C_{1-2} -hydroxyalkyl,

nitro,

 C_{2-3} -alkenyl,

 C_{2-3} -alkynyl,

15 C_{1-6} -haloalkoxy,

 C_{1-6} -carboxyalkyl,

5-6-membered heterocyclyl- C_{1-6} -alkylamino,

unsubstituted or substituted phenyl and

unsubstituted or substituted 4-6 membered

heterocyclyl;

wherein R^4 is selected from a direct bond, C_{1-4} -alkyl, and

wherein R^e and R^f are independently selected from H and C_{1-2} -haloalkyl; and

- wherein R⁷ is selected from H, C₁₋₃-alkyl, optionally substituted phenyl, optionally substituted phenyl-C₁₋₃-alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C₁₋C₃-alkyl, C₁₋₃-alkoxy-C₁₋₂-alkyl and C₁₋₃-alkoxy-C₁₋₃-alkoxy-C₁₋₃-alkyl; and pharmaceutically acceptable derivatives thereof.
 - 22. Compound of Claim 21 wherein R is selected from indazolyl, where R is unsubstituted or substituted with one

or more substituents selected from chloro, fluoro, amino, hydroxy, methyl, ethyl, propyl, trifluoromethyl, dimethylaminopropynyl, 1-methylpiperdinylmethoxy, dimethylaminoethoxyethoxy, methoxy and ethoxy; wherein R¹ is selected from phenyl, tetrahydronaphthyl, indanyl, indenyl, naphthyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, isoquinolyl, quinolyl, indolyl, isoindolyl, 2,3-dihydro-1H-

- indolyl, naphthyridinyl, quinozalinyl, benzo[d]isothiazolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, tetrahydroquinolinyl, indazolyl, 2,1,3-benzothiadiazolyl, benzodioxanyl, benzothienyl, benzofuryl, benzimidazolyl, dihydro-
- benzimidazolyl, benzoxazolyl and benzthiazolyl, where R¹ is unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl,
- phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl,
 piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-
- Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl,
- 30 pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Bocpyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
 pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl,
 methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl,

aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3-ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1-methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl),

- 5 imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1di(trifluoromethyl)-1-hydroxymethyl, 1,1-
- di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(Nisopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy,
- phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and
- ethoxy; wherein R² is selected from H, chloro, fluoro, bromo, amino, hydroxy, methyl, ethyl, propyl, oxo, dimethylamino, aminosulfonyl, cyclopropyl, cyano, hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl,
- 25 morpholinylethylamino, propynyl, unsubstituted or substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl,

furanyl, pyridyl, imidazolyl, and pyrazolyl; and wherein ${\mbox{R}}^4$ is selected from a direct bond, ethyl, butyl, and

30 ; and pharmaceutically acceptable derivatives thereof.

23. A compound of Claim 1 having the formula V

$$R^2$$
 A^5
 R^4
 R^1
 R^4
 R^1

wherein A⁵ is selected from S, O and NR⁶;

5 wherein R is selected from unsubstituted or substituted 9or 10-membered fused nitrogen-containing heteroaryl,

wherein R is substituted with one or more substituents selected from halo, amino, hydroxy, C_{1-6} -alkyl, C_{1-6} -haloalkyl, C_{1-6} -alkoxy, optionally substituted heterocyclylalkoxy, C_{1-6} -alkylamino- C_{2-4} -alkynyl, C_{1-6} -

10 heterocyclylalkoxy, C_{1-6} -alkylamino- C_{2-4} -alkynyl, C_{1-6} -alkylamino- C_{1-6} -alkoxy, C_{1-6} -alkylamino- C_{1-6} -alkoxy- C_{1-6} -alkoxy, and optionally substituted heterocyclyl- C_{2-4} -alkynyl;

wherein $\ensuremath{\mbox{R}}^1$ is selected from unsubstituted or substituted aryl,

cycloalky1,

5-6 membered heteroary1 and
9-10 membered bicyclic and 13-14 membered
 tricyclic heterocycly1,

wherein substituted R¹ is substituted with one or more substituents selected from halo, C₁₋₆-alkyl, optionally substituted C₃₋₆-cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-C_{1-C4}-alkylenyl, C₁₋₂-haloalkoxy, optionally substituted phenyloxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-C_{1-C4}-alkylenyl, optionally substituted 4-6 membered heterocyclyl-C_{2-C4}-alkenylenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6

10

membered heterocyclyl-C₁₋₄-alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl-C₁₋₄-alkylcarbonyl, C₁₋₂-haloalkyl, C₁₋₄-aminoalkyl, nitro, amino, hydroxy, cyano, aminosulfonyl, C₁₋₂-alkylsulfonyl, halosulfonyl, C₁₋₄-alkylcarbonyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkoxy, C₁₋₄-alkoxycarbonyl, C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkyl, C₁₋₄-alkoxycarbonyl, C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkyl, C₁₋₄-alkoxycarbonyl

hydroxyalkyl, R^{2} and C_{1-4} -alkoxy;

wherein ${\ensuremath{R^2}}$ is one or more substituents independently selected from

Η,

15 halo,

hydroxy,

amino,

 C_{1-6} -alkyl,

 C_{1-6} -haloalkyl,

 C_{1-6} -alkoxy,

 C_{1-2} -alkylamino,

aminosulfonyl,

 C_{3-6} -cycloalkyl,

cyano,

 C_{1-2} -hydroxyalkyl,

nitro,

 C_{2-3} -alkenyl,

 C_{2-3} -alkynyl,

 C_{1-6} -haloalkoxy,

 C_{1-6} -carboxyalkyl,

5-6-membered heterocyclyl- C_{1-6} -alkylamino,

unsubstituted or substituted phenyl and

unsubstituted or substituted 4-6 membered
heterocyclyl;

wherein R^4 is selected from a direct bond, C_{1-4} -alkyl, and

5 wherein R^e and R^f are independently selected from H and C_{1-2} -haloalkyl;

wherein R⁶ is H or C₁₋₆-alkyl; and
wherein R⁷ is selected from H, C₁₋₃-alkyl, optionally
substituted phenyl, optionally substituted phenyl-C₁₋₃alkyl, 4-6 membered heterocyclyl, optionally substituted
4-6 membered heterocyclyl-C₁₋C₃-alkyl, C₁₋₃-alkoxy-C₁₋₂alkyl and C₁₋₃-alkoxy-C₁₋₃-alkoxy-C₁₋₃-alkyl;
and pharmaceutically acceptable derivatives thereof.

- 24. Compound of Claim 23 wherein R is selected from indazolyl, where R is unsubstituted or substituted with one or more substituents selected from chloro, fluoro, amino, hydroxy, methyl, ethyl, propyl, trifluoromethyl, dimethylaminopropynyl, 1-methylpiperdinylmethoxy,
- dimethylaminoethoxyethoxy, methoxy and ethoxy; wherein R¹ is selected from phenyl, tetrahydronaphthyl, indanyl, indenyl, naphthyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl,
- isoquinoly1, quinoly1, indoly1, isoindoly1, 2,3-dihydro-1H-indoly1, naphthyridiny1, quinozaliny1, benzo[d]isothiazoly1, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoreny1, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinoly1, tetrahydroquinoliny1, indazoly1, 2,1,3-benzothiadiazoly1, benzodioxany1,
- benzothienyl, benzofuryl, benzimidazolyl, dihydrobenzimidazolyl, benzoxazolyl and benzthiazolyl, where R¹ is unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino,

cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl,

- piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-
- 4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
- pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl, methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4-methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl, aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3-ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-
- 20 methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl),
 imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl,
 hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, sec-butyl, trifluoromethyl, pentafluoroethyl,
- 25 nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1,1-di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1-hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-
- aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-

2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; wherein R² is selected from H, chloro, fluoro, bromo, amino, hydroxy, methyl, ethyl, propyl, oxo,

bromo, amino, hydroxy, methyl, ethyl, propyl, oxo, dimethylamino, aminosulfonyl, cyclopropyl, cyano, hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl, morpholinylethylamino, propynyl, unsubstituted or substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl,

furanyl, pyridyl, imidazolyl, and pyrazolyl; wherein \mbox{R}^4 is selected from a direct bond, ethyl, butyl, and

wherein R^6 is H or methyl;

15 and pharmaceutically acceptable derivatives thereof.

25. A compound of Claim 1 having the formula

20

25

10

wherein A⁵ is selected from S, O and NR⁶;
wherein R is selected from unsubstituted or substituted 9or 10-membered fused nitrogen-containing heteroaryl,
where R is substituted with one or more substituents
selected from halo, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆haloalkyl, C₁₋₆-alkoxy, optionally substituted
heterocyclylalkoxy, C₁₋₆-alkylamino-C₂₋₄-alkynyl, C₁₋₆alkylamino-C₁₋₆-alkoxy, C₁₋₆-alkylamino-C₁₋₆-alkoxy-C₁₋₆-

VI

alkoxy, and optionally substituted heterocyclyl- C_{2-4} -alkynyl;

wherein R^1 is selected from unsubstituted or substituted aryl,

5 cycloalkyl,

5-6 membered heteroaryl and

9-10 membered bicyclic and 13-14 membered tricyclic heterocyclyl,

wherein substituted R^1 is substituted with one or more substituents selected from halo, C_{1-6} -alkyl, optionally 10 substituted C_{3-6} -cycloalkyl, optionally substituted phenyl, optionally substituted phenyl- C_1 - C_4 -alkylenyl, C_{1-} 2-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-C1-C4alkylenyl, optionally substituted 4-6 membered 15 heterocyclyl- C_2 - C_4 -alkenylenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 20 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkylcarbonyl, C_{1-2} haloalkyl, C₁₋₄-aminoalkyl, nitro, amino, hydroxy, cyano, aminosulfonyl, $C_{1\text{--}2}\text{--alkylsulfonyl}$, halosulfonyl, $C_{1\text{--}4}\text{--}$ 25 alkylcarbonyl, C_{1-3} -alkylamino- C_{1-3} -alkyl, C_{1-3} -alkylamino- $\texttt{C}_{1\text{--}3}\text{--alkoxy, } \texttt{C}_{1\text{--}3}\text{--alkylamino-} \texttt{C}_{1\text{--}3}\text{--alkoxy-} \texttt{C}_{1\text{--}3}\text{--alkoxy, } \texttt{C}_{1\text{--}4}\text{--}$ alkoxycarbonyl, C_{1-4} -alkoxycarbonylamino- C_{1-4} -alkyl, C_{1-4} -

hydroxyalkyl, R^{e} R^{r} and C_{1-4} -alkoxy;

30 wherein R^2 is one or more substituents independently selected from

Η,

halo,

hydroxy,

amino,

 C_{1-6} -alkyl,

C1-6-haloalkyl,

5 C_{1-6} -alkoxy,

 C_{1-2} -alkylamino,

aminosulfonyl,

 C_{3-6} -cycloalkyl,

cyano,

10 C_{1-2} -hydroxyalkyl,

nitro,

 C_{2-3} -alkenyl,

 C_{2-3} -alkynyl,

 C_{1-6} -haloalkoxy,

15 C_{1-6} -carboxyalkyl,

5-6-membered heterocyclyl- C_{1-6} -alkylamino, unsubstituted or substituted phenyl and unsubstituted or substituted 4-6 membered

heterocyclyl;

20 wherein R^4 is selected from a direct bond, C_{1-4} -alkyl, and

wherein R^{e} and R^{f} are independently selected from H and C_{1-2} -haloalkyl;

wherein R^6 is H or C_{1-6} -alkyl; and

- wherein R^7 is selected from H, C_{1-3} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-3} -alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- $C_{1-}C_{3}$ -alkyl, C_{1-3} -alkoxy- C_{1-2} -alkyl and C_{1-3} -alkoxy- C_{1-3} -alkoxy- C_{1-3} -alkyl;
- 30 and pharmaceutically acceptable derivatives thereof.
 - 26. Compound of Claim 25 wherein R is selected from indazolyl, where R is unsubstituted or substituted with one


or more substituents selected from chloro, fluoro, amino, hydroxy, methyl, ethyl, propyl, trifluoromethyl, dimethylaminopropynyl, 1-methylpiperdinylmethoxy, dimethylaminoethoxyethoxy, methoxy and ethoxy; wherein R¹ is selected from phenyl, tetrahydronaphthyl, indanyl, indenyl, naphthyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, isoquinolyl, quinolyl, indolyl, isoindolyl, 2,3-dihydro-1H-indolyl, naphthyridinyl, quinozalinyl, benzo[d]isothiazolyl,

- indolyl, naphthyridinyl, quinozalinyl, benzo[d]isothiazolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, tetrahydroquinolinyl, indazolyl, 2,1,3-benzothiadiazolyl, benzodioxanyl, benzothienyl, benzofuryl, benzimidazolyl, dihydro-
- benzimidazolyl, benzoxazolyl and benzthiazolyl, where R¹ is unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl,
- phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-
- Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl,
- 30 pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Bocpyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
 pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl,
 methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl,

aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl),

- imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1di(trifluoromethyl)-1-hydroxymethyl, 1,1-
- di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-10 di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(Nisopropylamino) ethyl, dimethylaminoethoxy, 4-chlorophenoxy,
- phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, 15 pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and
- ethoxy; wherein R2 is selected from H, chloro, fluoro, 20 bromo, amino, hydroxy, methyl, ethyl, propyl, oxo, dimethylamino, aminosulfonyl, cyclopropyl, cyano, hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl,
- morpholinylethylamino, propynyl, unsubstituted or 25 substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl,

furanyl, pyridyl, imidazolyl, and pyrazolyl; wherein R4 is selected from a direct bond, ethyl, butyl, and



30

wherein R⁶ is H or methyl; and pharmaceutically acceptable derivatives thereof.

25

30

27. A compound of Claim 1 having the formula

$$R^2$$
 R^4
 R^4

wherein A⁵ is selected from S, O and NR⁶;
wherein R is selected from unsubstituted or substituted 9 or 10-membered fused nitrogen-containing heteroaryl,
where R is substituted with one or more substituents
selected from halo, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆haloalkyl, C₁₋₆-alkoxy, optionally substituted
heterocyclylalkoxy, C₁₋₆-alkylamino-C₂₋₄-alkynyl, C₁₋₆-alkylamino-C₁₋₆-alkoxy-C₁₋₆-alkoxy, and optionally substituted heterocyclyl-C₂₋₄-alkynyl;

wherein R^1 is selected from unsubstituted or substituted aryl,

cycloalkyl,

5-6 membered heteroaryl and 9-10 membered bicyclic and 13-14 membered

tricyclic heterocyclyl,
wherein substituted R¹ is substituted with one or more
substituents selected from halo, C¹-6-alkyl, optionally
substituted C³-6-cycloalkyl, optionally substituted
phenyl, optionally substituted phenyl-C¹-C⁴-alkylenyl, C¹²-haloalkoxy, optionally substituted phenyloxy,
optionally substituted 4-6 membered heterocyclyl-C¹-C⁴alkylenyl, optionally substituted 4-6 membered
heterocyclyl-C²-C⁴-alkenylenyl, optionally substituted 4-6
membered heterocyclyloxy, optionally substituted 4-6
membered heterocyclyloxy, optionally substituted 4-6

membered heterocyclyl-C₁₋₄-alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 5-4-6 membered heterocyclyl-C₁₋₄-alkylcarbonyl, C₁₋₂-haloalkyl, C₁₋₄-aminoalkyl, nitro, amino, hydroxy, cyano, aminosulfonyl, C₁₋₂-alkylsulfonyl, halosulfonyl, C₁₋₄-alkylcarbonyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkoxy, C₁₋₄-alkoxycarbonyl, C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkyl, C₁₋₄-

hydroxyalkyl, R^7 and C_{1-4} -alkoxy;

wherein ${\ensuremath{\mbox{R}}}^2$ is one or more substituents independently selected from

Η,

halo,

hydroxy, amino,

 C_{1-6} -alkyl,

 C_{1-6} -haloalkyl,

 C_{1-6} -alkoxy,

 C_{1-2} -alkylamino,

aminosulfonyl,

 C_{3-6} -cycloalkyl,

cyano,

 C_{1-2} -hydroxyalkyl,

nitro,

 C_{2-3} -alkenyl,

 C_{2-3} -alkynyl,

 C_{1-6} -haloalkoxy,

 C_{1-6} -carboxyalkyl,

5-6-membered heterocyclyl- C_{1-6} -alkylamino,

unsubstituted or substituted phenyl and

unsubstituted or substituted 4-6 membered heterocyclyl;

wherein R^4 is selected from a direct bond, C_{1-4} -alkyl, and

5 wherein R^e and R^f are independently selected from H and C_{1-2} -haloalkyl;

wherein R⁶ is H or C₁₋₆-alkyl; and
wherein R⁷ is selected from H, C₁₋₃-alkyl, optionally
substituted phenyl, optionally substituted phenyl-C₁₋₃alkyl, 4-6 membered heterocyclyl, optionally substituted
4-6 membered heterocyclyl-C₁₋C₃-alkyl, C₁₋₃-alkoxy-C₁₋₂alkyl and C₁₋₃-alkoxy-C₁₋₃-alkoxy-C₁₋₃-alkyl;
and pharmaceutically acceptable derivatives thereof.

- 28. Compound of Claim 27 wherein R is selected from indazolyl, where R is unsubstituted or substituted with one or more substituents selected from chloro, fluoro, amino, hydroxy, methyl, ethyl, propyl, trifluoromethyl, dimethylaminopropynyl, 1-methylpiperdinylmethoxy,
- dimethylaminoethoxyethoxy, methoxy and ethoxy; wherein R¹ is selected from phenyl, tetrahydronaphthyl, indanyl, indenyl, naphthyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl,
- isoquinolyl, quinolyl, indolyl, isoindolyl, 2,3-dihydro-1H-indolyl, naphthyridinyl, quinozalinyl, benzo[d]isothiazolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, tetrahydroquinolinyl, indazolyl, 2,1,3-benzothiadiazolyl, benzodioxanyl,
- benzothienyl, benzofuryl, benzimidazolyl, dihydrobenzimidazolyl, benzoxazolyl and benzthiazolyl, where R¹ is unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino,

cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl,

- piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-
- 4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, pyrrolidin-2-ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
- pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl,
 methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl,
 aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-
- 20 methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl),
 imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl,
 hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, sec-butyl, trifluoromethyl, pentafluoroethyl,
- 25 nonafluorobutyl, dimethylaminopropyl, 1,1di(trifluoromethyl)-1-hydroxymethyl, 1,1di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-
- aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-

2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; wherein R² is selected from H, chloro, fluoro, bromo, amino, hydroxy, methyl, ethyl, propyl, oxo,

dimethylamino, aminosulfonyl, cyclopropyl, cyano, hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl, morpholinylethylamino, propynyl, unsubstituted or substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl,

furanyl, pyridyl, imidazolyl, and pyrazolyl; wherein \mbox{R}^4 is selected from a direct bond, ethyl, butyl, and

wherein R⁶ is H or methyl;

15 and pharmaceutically acceptable derivatives thereof.

29. Compound of Claim 1 of the formulas

20

10

wherein A^5 is selected from S, O and NR^6 ; wherein R is selected from

unsubstituted or substituted 9- or 10-membered fused nitrogen-containing heteroary1,

where R is substituted with one or more substituents selected from halo, amino, hydroxy, C_{1-6} -alkyl, C_{1-6} -haloalkyl, C_{1-6} -alkoxy, optionally substituted heterocyclylalkoxy, C_{1-6} -alkylamino- C_{2-4} -alkynyl, C_{1-6} -

30

alkylamino- C_{1-6} -alkoxy, C_{1-6} -alkylamino- C_{1-6} -alkoxy- C_{1-6} -alkoxy, and optionally substituted heterocyclyl- C_{2-4} -alkynyl;

wherein R^1 is selected from unsubstituted or substituted aryl,

cycloalkyl,

5-6 membered heteroaryl and


9-10 membered bicyclic and 13-14 membered tricyclic heterocyclyl,

wherein substituted R^1 is substituted with one or more substituents selected from halo, C_{1-6} -alkyl, optionally substituted C_{3-6} -cycloalkyl, optionally substituted phenyl, optionally substituted phenyl- $C_{1-}C_{4}$ -alkylenyl, C_{1-} 2-haloalkoxy, optionally substituted phenyloxy,

optionally substituted 4-6 membered heterocyclyl-C₁₋C₄alkylenyl, optionally substituted 4-6 membered
heterocyclyl-C₂₋C₄-alkenylenyl, optionally substituted 4-6
membered heterocyclyl, optionally substituted 4-6
membered heterocyclyloxy, optionally substituted 4-6

membered heterocyclyl- C_{1-4} -alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkylcarbonyl, C_{1-2} -

haloalkyl, C₁₋₄-aminoalkyl, nitro, amino, hydroxy, cyano, aminosulfonyl, C₁₋₂-alkylsulfonyl, halosulfonyl, C₁₋₄-alkylcarbonyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkoxy, C₁₋₄-alkoxycarbonyl, C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkyl, C₁₋₄-



wherein ${\ensuremath{R^2}}$ is one or more substituents independently selected from

halo,

hydroxy,

amino,

 C_{1-6} -alkyl,

5 C₁₋₆-haloalkyl,

 C_{1-6} -alkoxy,

 C_{1-2} -alkylamino,

aminosulfonyl,

 C_{3-6} -cycloalkyl,

10 cyano,

 C_{1-2} -hydroxyalkyl,

nitro,

 C_{2-3} -alkenyl,

 C_{2-3} -alkynyl,

15 C_{1-6} -haloalkoxy,


 C_{1-6} -carboxyalkyl,

5-6-membered heterocyclyl- $C_{1\text{-}6}$ -alkylamino, unsubstituted or substituted phenyl and

unsubstituted or substituted 4-6 membered

heterocyclyl;

wherein R^4 is selected from a direct bond, C_{1-4} -alkyl, and



20

wherein R^e and R^f are independently selected from H and C_{1-2} -haloalkyl;

25 wherein R^6 is H or C_{1-6} -alkyl; and

wherein R^7 is selected from H, C_{1-3} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-3} -alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- $C_{1-}C_{3}$ -alkyl, C_{1-3} -alkoxy- C_{1-2} -

30 alkyl and C_{1-3} -alkoxy- C_{1-3} -alkoxy- C_{1-3} -alkyl;

and pharmaceutically acceptable derivatives thereof.

- 30. Compound of Claim 29 wherein R is selected from indazolyl, where R is unsubstituted or substituted with one or more substituents selected from chloro, fluoro, amino, hydroxy, methyl, ethyl, propyl, trifluoromethyl,
- dimethylaminopropynyl, 1-methylpiperdinylmethoxy, dimethylaminoethoxyethoxy, methoxy and ethoxy; wherein R¹ is selected from phenyl, tetrahydronaphthyl, indanyl, indenyl, naphthyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl,
- 10 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl,
 isoquinolyl, quinolyl, indolyl, isoindolyl, 2,3-dihydro-1H indolyl, naphthyridinyl, quinozalinyl, benzo[d]isothiazolyl,
 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro1,2,4-triazolo[3,4-a]isoquinolyl, tetrahydroquinolinyl,
- indazolyl, 2,1,3-benzothiadiazolyl, benzodioxanyl, benzothienyl, benzofuryl, benzimidazolyl, dihydrobenzimidazolyl, benzoxazolyl and benzthiazolyl, where R¹ is unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino,
- cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-
- 25 methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-
- 30 ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl,
 pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl,
 pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl,
 pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl,

methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl,
aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3ethoxycarbonyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1methylpiperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl),
imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl,
hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, sec-butyl, trifluoromethyl, pentafluoroethyl,

- 10 nonafluorobutyl, dimethylaminopropyl, 1,1di(trifluoromethyl)-1-hydroxymethyl, 1,1di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-
- aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, pyrrol-1-ylmethoxy, 1-methyl-pyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-
- 20 2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; wherein R² is selected from H, chloro, fluoro, bromo, amino, hydroxy, methyl, ethyl, propyl, oxo, dimethylamino, aminosulfonyl, cyclopropyl, cyano,
- hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl, morpholinylethylamino, propynyl, unsubstituted or substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl,
- furanyl, pyridyl, imidazolyl, and pyrazolyl; wherein R^4 is selected from a direct bond, ethyl, butyl, and

wherein R⁶ is H or methyl;

and pharmaceutically acceptable derivatives thereof.

31. Compound of Claim 1 of the formula

5

10

15

wherein A^5 is selected from S, O and NR^6 ; wherein R is selected from

unsubstituted or substituted 9- or 10-membered fused nitrogen-containing heteroaryl,

IX

where R is substituted with one or more substituents selected from halo, amino, hydroxy, C_{1-6} -alkyl, C_{1-6} -haloalkyl, C_{1-6} -alkoxy, optionally substituted heterocyclylalkoxy, C_{1-6} -alkylamino- C_{2-4} -alkynyl, C_{1-6} -alkylamino- C_{1-6} -alkoxy- C_{1-6} -alkoxy, and optionally substituted heterocyclyl- C_{2-4} -alkynyl;

wherein R^1 is selected from unsubstituted or substituted aryl,

20 cycloalkyl,

5-6 membered heteroaryl and

9-10 membered bicyclic and 13-14 membered tricyclic heterocyclyl,

wherein substituted R¹ is substituted with one or more

substituents selected from halo, C₁₋₆-alkyl, optionally
substituted C₃₋₆-cycloalkyl, optionally substituted
phenyl, optionally substituted phenyl-C₁₋C₄-alkylenyl, C₁₋₂-haloalkoxy, optionally substituted phenyloxy,
optionally substituted 4-6 membered heterocyclyl-C₁₋C₄-

alkylenyl, optionally substituted 4-6 membered heterocyclyl-C2-C4-alkenylenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl- $C_{1\text{--}4}$ -alkoxy, optionally substituted 5 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkylcarbonyl, C_{1-2} haloalkyl, C_{1-4} -aminoalkyl, nitro, amino, hydroxy, cyano, 10 aminosulfonyl, C_{1-2} -alkylsulfonyl, halosulfonyl, C_{1-4} alkylcarbonyl, C_{1-3} -alkylamino- C_{1-3} -alkyl, C_{1-3} -alkylamino- C_{1-3} -alkoxy, C_{1-3} -alkylamino- C_{1-3} -alkoxy- C_{1-3} -alkoxy, C_{1-4} alkoxycarbonyl, $C_{1\text{--}4}$ -alkoxycarbonylamino- $C_{1\text{--}4}$ -alkyl, $C_{1\text{--}4}$ -

15 hydroxyalkyl, R^{e} and C_{1-4} -alkoxy;

wherein R^2 is one or more substituents independently selected from

Η,

halo,

20 hydroxy,

amino,

 C_{1-6} -alkyl,

 C_{1-6} -haloalkyl,

 C_{1-6} -alkoxy,

 C_{1-2} -alkylamino,

aminosulfonyl,

 C_{3-6} -cycloalkyl,

cyano,

 C_{1-2} -hydroxyalkyl,

30 nitro,

 C_{2-3} -alkenyl,

 C_{2-3} -alkynyl,

 C_{1-6} -haloalkoxy,

 C_{1-6} -carboxyalkyl, 5-6-membered heterocyclyl- C_{1-6} -alkylamino, unsubstituted or substituted phenyl and unsubstituted or substituted 4-6 membered

wherein R^4 is selected from a direct bond, C_{1-4} -alkyl, and

heterocyclyl;

wherein R^e and R^f are independently selected from H and C_{1-2} -haloalkyl;

wherein R⁶ is H or C₁₋₆-alkyl; and wherein R⁷ is selected from H, C₁₋₃-alkyl, optionally substituted phenyl, optionally substituted phenyl-C₁₋₃-alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C₁₋C₃-alkyl, C₁₋₃-alkoxy-C₁₋₂-alkyl and C₁₋₃-alkoxy-C₁₋₃-alkoxy-C₁₋₃-alkyl; and pharmaceutically acceptable derivatives thereof.

32. Compound of Claim 31 wherein R is selected from indazolyl, where R is unsubstituted or substituted with one or more substituents selected from chloro, fluoro, amino, 20 hydroxy, methyl, ethyl, propyl, trifluoromethyl, dimethylaminopropynyl, 1-methylpiperdinylmethoxy, dimethylaminoethoxyethoxy, methoxy and ethoxy; wherein R^1 is selected from phenyl, tetrahydronaphthyl, indanyl, indenyl, naphthyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl, 25 thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinoly1, 1,2,3,4-tetrahydro-isoquinoly1, isoquinoly1, quinoly1, indoly1, isoindoly1, 2,3-dihydro-1Hindolyl, naphthyridinyl, quinozalinyl, benzo[d]isothiazolyl, benzo[d]isothiazoly1, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-30 fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, tetrahydroquinolinyl, indazolyl, 2,1,3-benzothiadiazolyl, benzodioxanyl, benzothienyl, benzofuryl, benzimidazolyl,

dihydro-benzimidazolyl, benzoxazolyl and benzthiazolyl, where R^1 is unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy,

- aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, methylpiperazinylmethyl, methylpiperazinylpropyl, morpholinylpropyl, methylpiperidinylmethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl,
- piperidinylethyl, piperidinylmethyl, piperidinylpropyl, pyrrolidinylpropyl, pyrrolidinylpropenyl, pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl, methylcarbonyl, piperidinylmethylcarbonyl, methylpiperazinylcarbonylethyl, methoxycarbonyl, 3-
- ethoxycarbonyl-2-methyl-fur-5-yl, methylpiperazinyl,
 methylpiperidyl, 1-methyl-(1,2,3,6-tetrahydropyridyl),
 imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl,
 hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tertbutyl, sec-butyl, trifluoromethyl, pentafluoroethyl,
- 20 nonafluorobutyl, dimethylaminopropyl, 1,1di(trifluoromethyl)-1-hydroxymethyl, 1,1di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-
- aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; wherein R² is selected from H, chloro, fluoro, bromo, amino, hydroxy, methyl, ethyl, propyl, oxo,
- dimethylamino, aminosulfonyl, cyclopropyl, cyano, hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl, morpholinylethylamino, propynyl, unsubstituted or

10

15

substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl,

furanyl, pyridyl, imidazolyl, and pyrazolyl; wherein ${\mbox{R}}^4$ is selected from a direct bond, ethyl, butyl, and

wherein R^6 is H or methyl; and pharmaceutically acceptable derivatives thereof.

33. Compound of Claim 1 of the formula

 R^{2} A^{6} A^{5} A^{12} A^{12}

wherein A^5 is selected from S, O and NR^6 ; wherein A^6 is selected from CR^2 and N; wherein R is selected from

unsubstituted or substituted 9- or 10-membered fused nitrogen-containing heteroary1,

x

where R is substituted with one or more substituents selected from halo, amino, hydroxy, C₁₋₆-alkyl, C₁₋₆-20 haloalkyl, C₁₋₆-alkoxy, optionally substituted heterocyclylalkoxy, C₁₋₆-alkylamino-C₂₋₄-alkynyl, C₁₋₆-alkylamino-C₁₋₆-alkoxy-C₁₋₆-alkoxy, and optionally substituted heterocyclyl-C₂₋₄-alkynyl;

wherein R^1 is selected from unsubstituted or substituted aryl,

n 21 jun - 003

cycloalkyl,

5-6 membered heteroaryl and

9-10 membered bicyclic and 13-14 membered tricyclic heterocyclyl,

- wherein substituted R^1 is substituted with one or more substituents selected from halo, C_{1-6} -alkyl, optionally substituted C_{3-6} -cycloalkyl, optionally substituted phenyl, optionally substituted phenyl- $C_{1-}C_4$ -alkylenyl, C_{1-2} -haloalkoxy, optionally substituted phenyloxy,
- optionally substituted 4-6 membered heterocyclyl-C₁-C₄-alkylenyl, optionally substituted 4-6 membered heterocyclyl-C₂-C₄-alkenylenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6
- membered heterocyclyl- C_{1-4} -alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl- C_{1-4} -alkylcarbonyl, C_{1-2} -
- haloalkyl, C_{1-4} -aminoalkyl, nitro, amino, hydroxy, cyano, aminosulfonyl, C_{1-2} -alkylsulfonyl, halosulfonyl, C_{1-4} -alkylcarbonyl, C_{1-3} -alkylamino- C_{1-3} -alkyl, C_{1-3} -alkylamino- C_{1-3} -alkoxy, C_{1-3} -alkylamino- C_{1-3} -alkoxy- C_{1-3} -alkoxy, C_{1-4} -alkoxycarbonyl, C_{1-4} -alkoxycarbonylamino- C_{1-4} -alkyl, C_{1-4} -

 $R^e \longrightarrow R^f$ and C_{1-4}

hydroxyalkyl, 0 and C_{1-4} -alkoxy; wherein R^2 is one or more substituents independently selected from

Η,

halo,

30 hydroxy,

25

amino,

 C_{1-6} -alkyl,

 C_{1-6} -haloalkyl,

 C_{1-6} -alkoxy,

 C_{1-2} -alkylamino,

aminosulfonyl,

 C_{3-6} -cycloalkyl,

5 cyano,

 C_{1-2} -hydroxyalkyl,

nitro,

 C_{2-3} -alkenyl,

 C_{2-3} -alkynyl,

10 C_{1-6} -haloalkoxy,

 C_{1-6} -carboxyalkyl,

5-6-membered heterocyclyl- $C_{1\text{-}6}$ -alkylamino, unsubstituted or substituted phenyl and

unsubstituted or substituted 4-6 membered

15 heterocyclyl;

wherein R^4 is selected from a direct bond, C_{1-4} -alkyl, and

wherein R^e and R^f are independently selected from H and C_{1-2} -haloalkyl;

20 wherein R⁶ is H or C₁₋₆-alkyl;

25

wherein R^7 is selected from H, C_{1-3} -alkyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-3} -alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl- $C_{1-}C_{3}$ -alkyl, C_{1-3} -alkoxy- C_{1-2} -

alkyl and C_{1-3} -alkoxy- C_{1-3} -alkoxy- C_{1-3} -alkyl; and wherein

a)
$$R^{10}$$
 is H ; or R^{4} R^{1} is -NHR, R^{12} is H , and R^{13}

10

b)
$$R^{10}$$
 is -NHR, R^{11} is H , or R^{12} is H , and R^{13}

c)
$$R^{10}$$
 is H, R^{11} is -NHR, R^{12} is H , and R^{13} is H; or

d)
$$R^{10}$$
 is H, R^{11} is H^{11} is H^{12} is -NHR, and H^{13} is H; or

e)
$$R^{10}$$
 is H, R^{11} is H, R^{12} is H , H , and H , and H is -NHR; or

f) R^{10} is H, R^{11} is H, R^{12} is -NHR, and R^{13} is $\frac{1}{H}$; and pharmaceutically acceptable derivatives thereof.

34. Compound of Claim 33 wherein R is selected from indazolyl, where R is unsubstituted or substituted with one

or more substituents selected from chloro, fluoro, amino,

hydroxy, methyl, ethyl, propyl, trifluoromethyl, dimethylaminopropynyl, 1-methylpiperdinylmethoxy, dimethylaminoethoxyethoxy, methoxy and ethoxy; wherein R¹ is selected from phenyl, tetrahydronaphthyl, indanyl, indenyl, naphthyl, cyclohexyl, isoxazolyl, pyrazolyl, thiazolyl,

thiadiazolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, isoquinolyl, quinolyl, indolyl, isoindolyl, 2,3-dihydro-1H-indolyl, naphthyridinyl, quinozalinyl, benzo[d]isothiazolyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-

25 1,2,4-triazolo[3,4-a]isoquinolyl, tetrahydroquinolinyl,

indazolyl, 2,1,3-benzothiadiazolyl, benzodioxanyl, benzothienyl, benzofuryl, benzimidazolyl, dihydrobenzimidazolyl, benzoxazolyl and benzthiazolyl, where R¹ is unsubstituted or substituted with one or more substituents

- selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, methylpiperazinylmethyl, methylpiperazinylpropyl, morpholinylpropyl,
- methylpiperidinylmethyl, morpholinylethyl, 1-(4morpholinyl)-2,2-dimethylpropyl, piperidinylethyl,
 piperidinylmethyl, piperidinylpropyl, pyrrolidinylpropyl,
 pyrrolidinylpropenyl, pyrrolidinylbutenyl, fluorosulfonyl,
 methylsulfonyl, methylcarbonyl, piperidinylmethylcarbonyl,
- 15 methylpiperazinylcarbonylethyl, methoxycarbonyl, 3ethoxycarbonyl-2-methyl-fur-5-yl, methylpiperazinyl,
 methylpiperidyl, 1-methyl-(1,2,3,6-tetrahydropyridyl),
 imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl,
 hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tert-
- butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl)-1-hydroxymethyl, 1,1-di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1-
- 25 hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1aminoethyl, 2-aminoethyl, 1-(N-isopropylamino)ethyl, 2-(Nisopropylamino)ethyl, dimethylaminoethoxy, 4-chlorophenoxy,
 phenyloxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and
 ethoxy; wherein R² is selected from H, chloro, fluoro,
- 30 bromo, amino, hydroxy, methyl, ethyl, propyl, oxo, dimethylamino, aminosulfonyl, cyclopropyl, cyano, hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl, morpholinylethylamino, propynyl, unsubstituted or

2.0

substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl,


furanyl, pyridyl, imidazolyl, and pyrazolyl; wherein ${\mbox{R}}^4$ is selected from a direct bond, ethyl, butyl, and

wherein R⁶ is H or methyl;

and pharmaceutically acceptable derivatives thereof.

- 35. A pharmaceutical composition comprising a

 10 pharmaceutically-acceptable carrier and a compound as in any
 of Claims 1-34.
- 36. A method of treating cancer in a subject, said method comprising administering an effective amount of a compound of formula I



wherein each of ${\tt A}^1$ and ${\tt A}^2$ is independently C or N; wherein ring A is selected from

- a) 5- or 6-membered partially saturated heterocyclyl,
- b) 5- or 6-membered heteroaryl,
- c) 9-, 10- or 11-membered fused partially saturated heterocyclyl,
- d) 9- or 10-membered fused heteroaryl,
 - e) aryl, and
 - f) 4-, 5- or 6-membered cycloalkenyl;

$$R^4$$

wherein X is

wherein ${\bf Z}$ is oxygen or sulfur;

wherein R is selected from

- a) substituted or unsubstituted 4-6 membered heterocyclyl,
 - b) substituted aryl, and
- c) substituted or unsubstituted fused 9-14-membered bicyclic or tricyclic heterocyclyl;

wherein substituted R is substituted with one or more substituents independently selected from halo, -OR³, -SR³, -SO₂R³, -CO₂R³, -CONR³R³, -COR³, -NR³R³, -SO₂NR³R³, -NR³C(O)OR³, -NR³C(O)R³, cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, nitro, alkylaminoalkoxyalkoxy, cyano, alkylaminoalkoxy, lower alkyl substituted with R², lower alkenyl substituted with R², and lower alkynyl substituted with R²;

wherein R1 is selected from

- a) substituted or unsubstituted 6-10 membered aryl,
- 20 b) substituted or unsubstituted 4-6 membered heterocycly1,
 - c) substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl,
 - d) cycloalkyl, and
- 25 e) cycloalkenyl,

wherein substituted R^1 is substituted with one or more substituents independently selected from halo, $-OR^3$, $-SR^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-NH(C_1-C_4$ alkylenyl R^{14}), $-SO_2R^3$, $-SO_2NR^3R^3$, $-NR^3C(0)OR^3$, $-NR^3C(0)R^3$, optionally substituted cycloalkyl, optionally substituted 4-6 membered heterocyclyl,

10

optionally substituted phenyl, halosulfonyl, cyano, alkylaminoalkoxy, alkylaminoalkoxyalkoxy, nitro, lower alkyl substituted with R^2 , lower alkenyl substituted with R^2 , and lower alkynyl substituted with R^2 ;

wherein R² is one or more substituents independently selected from H, halo, -OR³, oxo, -SR³, -CO₂R³, -COR³, -CONR³R³, -NR³C(O)OR³, -NR³C(O)R³, cycloalkyl, optionally substituted phenylalkylenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted heteroarylalkylenyl, optionally substituted phenyl, lower alkyl, cyano, lower hydroxyalkyl, lower carboxyalkyl, nitro, lower alkenyl, lower alkynyl, lower aminoalkyl, lower alkylaminoalkyl and lower haloalkyl;

wherein R³ is selected from H, lower alkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted C₃-C₆-cycloalkyl, optionally substituted phenylalkyl, optionally substituted 4-6 membered heterocyclylalkyl, optionally substituted C₃-C₆ cycloalkylalkyl, and lower haloalkyl;

wherein R^4 is selected from a direct bond, C_{2-4} -alkylenyl, C_{2-4} -alkenylenyl and C_{2-4} -alkynylenyl, where one of the CH_2 groups may be replaced with an oxygen atom or an -NH-, wherein R^4 is optionally substituted with hydroxy;

wherein R⁵ is selected from H, lower alkyl, optionally substituted phenyl and optionally substituted lower aralkyl;

wherein R¹⁴ is selected from H, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl and optionally substituted C₃-C₆ cycloalkyl; and pharmaceutically acceptable derivatives thereof; provided R is not unsubstituted 2-thienyl, 2-pyridyl or 3-pyridyl.


37. The method of Claim 36 comprising a combination with a compound selected from antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and miscellaneous agents.

38. A method of treating angiogenesis in a subject, said method comprising administering an effective amount of a compound as in any of Formula I

10


15

5



wherein each of ${\tt A}^1$ and ${\tt A}^2$ is independently C or N; wherein ring A is selected from

- a) 5- or 6-membered partially saturated heterocyclyl,
- b) 5- or 6-membered heteroaryl,
- c) 9-, 10- or 11-membered fused partially saturated heterocyclyl,
- d) 9- or 10-membered fused heteroaryl,
- 20 e) aryl, and
 - f) 4-, 5- or 6-membered cycloalkenyl;



wherein X is

wherein Z is oxygen or sulfur; wherein R is selected from

- a) substituted or unsubstituted 4-6 membered heterocyclyl,
- b) substituted aryl, and
- c) substituted or unsubstituted fused 9-14-membered bicyclic or tricyclic heterocyclyl;

wherein substituted R is substituted with one or more substituents independently selected from halo, -OR³, -SR³, -SO₂R³, -CO₂R³, -CONR³R³, -COR³, -NR³R³, -SO₂NR³R³, -NR³C(O)OR³, -NR³C(O)R³, cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, nitro, alkylaminoalkoxyalkoxy, cyano, alkylaminoalkoxy, lower alkyl substituted with R², lower alkenyl substituted with R², and lower alkynyl substituted with R²;

- 15 wherein R¹ is selected from
 - a) substituted or unsubstituted 6-10 membered aryl,
 - b) substituted or unsubstituted 4-6 membered heterocyclyl,
 - c) substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl,
 - d) cycloalkyl, and
 - e) cycloalkenyl,

20

wherein substituted R¹ is substituted with one or more substituents independently selected from halo, -OR³, -SR³, -CO₂R³, -CONR³R³, -COR³, -NR³R³, -NH(C₁-C₄ alkylenylR¹⁴), -SO₂R³, -SO₂NR³R³, -NR³C(O)OR³, -NR³C(O)R³, optionally substituted cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, halosulfonyl, cyano, alkylaminoalkoxy, alkylaminoalkoxyalkoxy, nitro, lower alkyl substituted with R², lower alkenyl substituted with R², and lower alkynyl substituted with R²;

haloalkyl;

wherein R^2 is one or more substituents independently selected from H, halo, $-OR^3$, oxo, $-SR^3$, $-CO_2R^3$, $-COR^3$, $-CONR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)R^3$, cycloalkyl, optionally substituted phenylalkylenyl, optionally

substituted 4-6 membered heterocyclyl, optionally substituted heteroarylalkylenyl, optionally substituted phenyl, lower alkyl, cyano, lower hydroxyalkyl, lower carboxyalkyl, nitro, lower alkenyl, lower alkynyl, lower aminoalkyl, lower alkylaminoalkyl and lower haloalkyl;

wherein R³ is independently selected from H, lower alkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted C₃-C₆-cycloalkyl, optionally substituted phenylalkyl, optionally substituted 4-6 membered heterocyclylalkyl, optionally substituted C₃-C₆ cycloalkylalkyl, and lower

wherein R^4 is selected from a direct bond, C_{2-4} -alkylenyl, C_{2-4} -alkenylenyl and C_{2-4} -alkynylenyl, where one of the CH_2 groups may be replaced with an oxygen atom or an -NH-, wherein R^4 is optionally substituted with hydroxy;

wherein R⁵ is selected from H, lower alkyl, optionally substituted phenyl and optionally substituted lower aralkyl;

wherein R¹⁴ is selected from H, optionally substituted


phenyl, optionally substituted 4-6 membered heterocyclyl
and optionally substituted C₃-C₆ cycloalkyl;
and pharmaceutically acceptable derivatives thereof;
provided R is not unsubstituted 2-thienyl, 2-pyridyl or 3pyridyl.

30

20

39. A compound as in any of Claims 1-34 for use in a method of therapeutic treatment for the human or animal body.

40. A method of treating KDR-related disorders in a mammal, said method comprising administering an effective amount of a compound of Formula I



5

20


25

wherein each of A^1 and A^2 is independently C or N; wherein ring A is selected from

a) 5- or 6-membered partially saturated heterocyclyl,

I

- 10 b) 5- or 6-membered heteroaryl,
 - c) 9-, 10- or 11-membered fused partially saturated heterocyclyl,
 - d) 9- or 10-membered fused heteroaryl,
 - e) aryl, and
- f) 4-, 5- or 6-membered cycloalkenyl;



wherein X is

wherein Z is oxygen or sulfur;

wherein R is selected from

- a) substituted or unsubstituted 4-6 membered heterocyclyl,
- b) substituted aryl, and
- c) substituted or unsubstituted fused 9-14-membered bicyclic or tricyclic heterocyclyl; wherein substituted R is substituted with one or more substituents independently selected from halo, -OR³,

t third all all pairs all after the

and the second second

the company to the consequent of the second

20

25

30

 $-SR^3$, $-SO_2R^3$, $-CO_2R^3$, $-CONR^3R^3$, $-COR^3$, $-NR^3R^3$, $-SO_2NR^3R^3$, $-NR^3C(O)OR^3$, $-NR^3C(O)R^3$, cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, nitro, alkylaminoalkoxyalkoxy, cyano, alkylaminoalkoxy, lower alkyl substituted with R^2 , lower alkenyl substituted with R^2 , and lower alkynyl substituted with R^2 ;

wherein R1 is selected from

- a) substituted or unsubstituted 6-10 membered aryl,
- b) substituted or unsubstituted 4-6 membered heterocyclyl,
 - c) substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl,
 - d) cycloalkyl, and
- 15 e) cycloalkenyl,

wherein substituted R¹ is substituted with one or more substituents independently selected from halo, -OR³, -SR³, -CO₂R³, -CONR³R³, -COR³, -NR³R³, -NH(C₁-C₄ alkylenylR¹⁴), -SO₂R³, -SO₂NR³R³, -NR³C(O)OR³, -NR³C(O)R³, optionally substituted cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, halosulfonyl, cyano, alkylaminoalkoxy, alkylaminoalkoxyalkoxy, nitro, lower alkyl substituted with R², lower alkenyl substituted with R², and lower alkynyl substituted with R²;

wherein R² is one or more substituents independently selected from H, halo, -OR³, oxo, -SR³, -CO₂R³, -COR³, -CONR³R³, -NR³C(O)OR³, -NR³C(O)R³, cycloalkyl, optionally substituted phenylalkylenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenylalkylenyl, optionally substituted phenyl, lower alkyl, cyano, lower hydroxyalkyl, lower

carboxyalkyl, nitro, lower alkenyl, lower alkynyl, lower aminoalkyl, lower alkylaminoalkyl and lower haloalkyl;

wherein R³ is independently selected from H, lower alkyl, optionally substituted phenyl, optionally substituted 4-6 optionally substituted membered heterocyclyl, optionally substituted C₃-C₆-cycloalkyl, optionally substituted phenylalkyl, optionally substituted 4-6 membered heterocyclylalkyl, optionally substituted C₃-C₆ cycloalkylalkyl, and lower haloalkyl;


wherein R^4 is selected from a direct bond, C_{2-4} -alkylenyl, C_{2-4} -alkenylenyl and C_{2-4} -alkynylenyl, where one of the CH_2 groups may be replaced with an oxygen atom or an -NH-, wherein R^4 is optionally substituted with hydroxy;

wherein R⁵ is selected from H, lower alkyl, optionally substituted phenyl and optionally substituted lower aralkyl;

wherein R^{14} is selected from H, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl and optionally substituted C_3 - C_6 cycloalkyl;

and pharmaceutically acceptable derivatives thereof; provided R is not unsubstituted 2-thienyl, 2-pyridyl or 3-pyridyl.

41. A method of treating proliferation-related
25 disorders in a mammal, said method comprising administering
an effective amount of a compound of Formula I



I

wherein each of A^1 and A^2 is independently C or N; wherein ring A is selected from

- a) 5- or 6-membered partially saturated heterocyclyl,
- 5 b) 5- or 6-membered heteroaryl,
 - c) 9-, 10- or 11-membered fused partially saturated heterocyclyl,
 - d) 9- or 10-membered fused heteroaryl,
 - e) aryl, and
- f) 4-, 5- or 6-membered cycloalkenyl;

$$R^4$$

wherein X is

15

wherein Z is oxygen or sulfur;

wherein R is selected from

- a) substituted or unsubstituted 4-6 membered heterocyclyl,
- b) substituted aryl, and
 - c) substituted or unsubstituted fused 9-14-membered bicyclic or tricyclic heterocyclyl;

wherein substituted R is substituted with one or more

substituents independently selected from halo, -OR³,
-SR³, -SO₂R³, -CO₂R³, -CONR³R³, -COR³, -NR³R³, -SO₂NR³R³,
-NR³C(O)OR³, -NR³C(O)R³, cycloalkyl, optionally
substituted 4-6 membered heterocyclyl, optionally
substituted phenyl, nitro, alkylaminoalkoxyalkoxy,

cyano, alkylaminoalkoxy, lower alkyl substituted
with R², lower alkenyl substituted with R², and
lower alkynyl substituted with R²;

wherein R1 is selected from

- a) substituted or unsubstituted 6-10 membered aryl,
- 30 b) substituted or unsubstituted 4-6 membered heterocyclyl,

- c) substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl,
- d) cycloalkyl, and
- e) cycloalkenyl,
- wherein substituted R¹ is substituted with one or more substituents independently selected from halo, -OR³, -SR³, -CO₂R³, -CONR³R³, -COR³, -NH(C₁-C₄ alkylenylR¹⁴), -SO₂R³, -SO₂NR³R³, -NR³C(O)OR³, -NR³C(O)R³, optionally substituted cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, halosulfonyl, cyano,
- optionally substituted phenyl, halosulfonyl, cyano, alkylaminoalkoxy, alkylaminoalkoxyalkoxy, nitro, lower alkyl substituted with R², lower alkenyl substituted with R², and lower alkynyl substituted with R²;
 - wherein R^2 is one or more substituents independently selected from H, halo, $-OR^3$, oxo, $-SR^3$, $-CO_2R^3$, $-COR^3$, $-CONR^3R^3$, $-NR^3C(0)OR^3$, $-NR^3C(0)R^3$, cycloalkyl, optionally substituted phenylalkylenyl, optionally
- substituted 4-6 membered heterocyclyl, optionally substituted heteroarylalkylenyl, optionally substituted phenyl, lower alkyl, cyano, lower hydroxyalkyl, lower carboxyalkyl, nitro, lower alkenyl, lower alkynyl, lower aminoalkyl, lower alkylaminoalkyl and lower haloalkyl;
- wherein R³ is independently selected from H, lower alkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted C₃-C₆-cycloalkyl, optionally substituted phenylalkyl, optionally substituted 4-6 membered heterocyclylalkyl, optionally substituted C₂-C₃ cycloalkylalkyl, and lower
- optionally substituted C_3 - C_6 cycloalkylalkyl, and lower haloalkyl;
 - wherein R^4 is selected from a direct bond, $C_{2\text{-}4}\text{-}alkylenyl,} C_{2\text{-}4}\text{-}alkenylenyl$ and $C_{2\text{-}4}\text{-}alkynylenyl,}$ where one of the CH_2

groups may be replaced with an oxygen atom or an -NH-, wherein R⁴ is optionally substituted with hydroxy; wherein R⁵ is selected from H, lower alkyl, optionally substituted phenyl and optionally substituted lower aralkyl;

wherein R^{14} is selected from H, optionally substituted phenyl, optionally substituted 4-6 membered heterocyclyl and optionally substituted C_3 - C_6 cycloalkyl; and pharmaceutically acceptable derivatives thereof; provided R is not unsubstituted 2-thienyl, 2-pyridyl or 3-pyridyl.

42. Method of Claim 41 wherein the disorder is inflammation or an inflammation-related disorder.

15

25

10

- 43. Compound of Claim 1 and pharmaceutically acceptable salts thereof selected from 2-(1H-Indazol-6-ylamino)-N-[3-(3-morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide;
- 20 2-(1H-Indazol-6-ylamino)-N-[3-(3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenyl]-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(1-methyl-piperidin-4-ylmethyl)-5-trifluoromethyl-phenyl]-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(1-methyl-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(piperidin-4-yloxy)-5trifluoromethyl-phenyl]-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(piperidin-4-ylmethoxy)-5trifluoromethyl-phenyl]-nicotinamide;
- 30 N-(3,3-Dimethyl-1,1-dioxo-2,3-dihydro-1H-116-benzo[d]isothiazol-6-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-nicotinamide;

- 2-(1H-Indazol-6-ylamino)-N-[3-(1-methyl-piperidin-4-ylmethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide;
- 2-(1H-Indazol-6-ylamino)-N-[3-(1-isopropyl-piperidin-4-ylmethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide;
- 5 N-[3-(2-Hydroxy-3-pyrrolidin-1-yl-propoxy)-4pentafluoroethyl-phenyl]-2-(1H-indazol-6-ylamino)nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[4-pentafluoroethyl-3-(2-piperidin-1-yl-ethoxy)-phenyl]-nicotinamide;
- - 2-(1H-Indazol-6-ylamino)-N-[4-pentafluoroethyl-3-(pyrrolidin-2-ylmethoxy)-phenyl]-nicotinamide;
- - 2-(1H-Indazol-6-ylamino)-N-[3-(pyrrolidin-2-ylmethoxy)-4-trifluoromethyl-phenyl]-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(2-pyrrolidin-1-yl-ethoxy)-4trifluoromethyl-phenyl]-nicotinamide;
 - N-(1-Acety1-3,3-dimethy1-2,3-dihydro-1H-indol-6-y1)-2-(1H-indazol-6-ylamino)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-{4-[1-methyl-1-(1-methyl-piperidin-4-yl)-ethyl]-phenyl}-nicotinamide;
- N-(4-Acetyl-2,2-dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(1-methyl-piperidin-4-yl)-5-trifluoromethyl-phenyl]-nicotinamide;
 - N-(3-Bromo-5-trifluoromethyl-phenyl)-2-(1H-indazol-6-ylamino)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-(2,2,4-trimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-nicotinamide;
 - N-[4-tert-Butyl-3-(pyrrolidin-2-ylmethoxy)-phenyl]-2-(1H-indazol-6-ylamino)-nicotinamide;

20

- N-(7-Acetyl-5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;
- 1-Boc-2-(2-tert-Butyl-5-{[2-(1H-indazol-6-ylamino)-pyridine-3-carbonyl]-amino}-phenoxymethyl)-pyrrolidine;
- 5 N-[4-tert-Butyl-3-(piperidin-4-ylmethoxy)-phenyl]-2-(1H-indazol-6-ylamino)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide;
 - N-(4-tert-Butyl-3-piperazin-1-yl-phenyl)-2-(1H-indazol-6-ylamino)-nicotinamide;
 - N-(3,3-dimethyl-2,3-dihydro-1H-indol-6-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;
 - N-(3,3-Dimethyl-1-piperidin-4-yl-2,3-dihydro-1H-indol-6-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;
- N-(2,2-Dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;
 - N-[4-tert-Butyl-3-(4-propyl-piperazin-1-yl)-phenyl]-2-(1H-indazol-6-ylamino)-nicotinamide;
 - N-[4-tert-Butyl-3-(4-isopropyl-piperazin-1-yl)-phenyl]-2-(1H-indazol-6-ylamino)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(1-methylpyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide;
 - N-(4,4-Dimethyl-1-oxo-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;
- 25 N-(3,3-Dimethyl-2,3-dihydro-benzofuran-6-yl)-2-(1H-indazol-6-ylamino)-nicotinamide;
 - N-[1-(2-Dimethylamino-acetyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]-2-(1H-indazol-6-ylamino)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(4-methyl-piperazin-1-ylmethyl)-4-pentafluoroethyl-phenyl]-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(4-Boc-piperazin-1-ylmethyl)-4-pentafluoroethyl-phenyl]-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-(3-morpholin-4-ylmethyl-4-pentafluoroethyl-phenyl)-nicotinamide;

- 2-(1H-Indazol-6-ylamino)-N-(4-pentafluoroethyl-3-piperazin-1-ylmethyl-phenyl)-nicotinamide;
- N-[4-tert-Butyl-3-(4-Boc-piperazin-1-yl)-phenyl]-2-(1H-indazol-6-ylamino)-nicotinamide;
- 5 N-(4-tert-Butyl-3-nitro-phenyl)-2-(1H-indazol-6-ylamino)-nicotinamide;
 - N-(3-Amino-4-tert-butyl-phenyl)-2-(1H-indazol-6-ylamino)nicotinamide;
- N-[4-tert-Butyl-3-(2-hydroxy-ethylamino)-phenyl]-2-(1H-10 indazol-6-ylamino)-nicotinamide;
 - N-[4-tert-Butyl-3-(2-morpholin-4-yl-ethylamino)-phenyl]-2-(1H-indazol-6-ylamino)-nicotinamide;
 - N-[4-tert-Butyl-3-(1-Boc-piperidin-4-ylamino)-phenyl]-2-(1H-indazol-6-ylamino)-nicotinamide;
- 2-(1H-Indazol-6-ylamino)-N-[2-(2-morpholin-4-yl-ethyl)-1,2,3,4-tetrahydro-isoquinolin-7-yl]-nicotinamide;
 - N-[4-tert-Buty1-2-(4-methyl-piperazin-1-yl)-phenyl]-2-(1H-indazol-6-ylamino)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-(2-oxo-4-trifluoromethyl-2H-chromen-7-yl)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-[3-(1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-5-trifluoromethyl-phenyl]-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-(1H-indol-7-yl)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-(4-pentafluoroethyl-phenyl)-nicotinamide;
 - N-[4-tert-Butyl-3-(piperidin-4-ylamino)-phenyl]-2-(1H-indazol-6-ylamino)-nicotinamide;
 - 2-(1H-Indazol-6-ylamino)-N-(3-piperazin-1-ylmethyl-5-trifluoromethyl-phenyl)-nicotinamide; and
- 30 N-(4,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(1H-indazol-6-ylamino)-nicotinamide.